Home » Healthcare » Pharmaceuticals » Antibody Drug Conjugate Market

Antibody Drug Conjugate Market By Product (Kadcyla, Enhertu, Adcetris, Padcev, Trodelvy, Polivy, Others); By Disease Type (Breast Cancer, Blood Cancer, Others); By Linker Type (Non-Cleavable, Cleavable); By Target (HER2, CD22, CD30, Others); By Payload Type (MMAE/Auristatin, Calicheamicin, Maytansinoids, Others); By Region – Growth, Share, Opportunities & Competitive Analysis, 2024 – 2032

Summary
Table Of Content

REPORT ATTRIBUTE	DETAILS
Historical Period	2019-2022
Base Year	2023
Forecast Period	2024-2032
Antibody Drug Conjugate Market Size 2023	USD 9984.20 Million
Antibody Drug Conjugate Market, CAGR	11.50%
Antibody Drug Conjugate Market Size 2032	USD 26594.21 Million

Market Insights

The demand for antibody drug conjugate was valued at USD 9984.20 million in 2023 and is expected to reach USD 26594.21 million in 2032, growing at a CAGR of 11.50% between 2024 and 2032.
The Kadcyla segment was the market leader by Product, accounting for the highest share in value in 2023, and the Enhert segment is expected to grow rapidly throughout the forecast period.

The Breast Cancer segment was the market leader by Disease Type, accounting for the highest share in value in 2023, and the Blood Cancer segment is expected to grow rapidly throughout the forecast period.
The Cleavable segment was the market leader by Linker Type, accounting for the highest share in value in 2023, and the non-cleavable Linkers segment is expected to grow rapidly throughout the forecast period.
The CD30-targeted ADCs segment is predicted to grow fastest over the projection period, while HER2 had the largest share by Target in 2023.
The MMAE/Auristatin segment was the market leader by Payload Type, accounting for the highest share in value in 2023, and the Maytansinoids segment is expected to grow rapidly throughout the forecast period.
North America is dominating the antibody-drug conjugate industry, with over one-third of the market in 2023.

The market’s primary possibilities include advancements in biotechnology, expanding applications beyond oncology, and increasing collaborations for innovative therapies.

Executive Summary

Market Definition

An antibody-drug conjugate (ADC) is a targeted cancer therapy that combines an antibody specific to cancer cells with a cytotoxic drug. It is manufactured through a multi-step process involving the selection of an appropriate antibody, conjugation of the antibody to a potent drug via a chemical linker, and rigorous testing to ensure stability and efficacy.

The antibody component of the ADC binds to specific antigens on the surface of cancer cells, allowing for precise targeting. Once bound, the ADC is internalized by the cancer cell, where the cytotoxic drug is released to destroy the cell from within. This targeted approach minimizes damage to healthy cells and enhances the therapeutic index of the treatment.

The advantage of antibody-drug conjugates is their ability to specifically target and kill cancer cells while minimizing damage to healthy tissues, thereby reducing side effects and improving treatment efficacy.

Access crucial information at unmatched prices!

Request your free sample report today & start making informed decisions powered by Credence Research!

Download Free Sample

Market Overview

The global antibody drug conjugate market has witnessed steady growth in recent years and is expected to grow at a CAGR of 11.50% between 2024 and 2032. The market was valued at USD 9984.20 million in 2023 and is expected to reach USD 26594.21 million in 2032.

The increasing prevalence of cancer globally is a significant factor driving the growth of the Antibody Drug Conjugate market. As the incidence of various cancers rises, there is an urgent need for more effective treatments. ADCs represent a promising class of drugs that offer targeted cancer therapy, combining the specificity of antibodies with the potent cell-killing ability of cytotoxic drugs. This dual action makes ADCs particularly effective in treating different types of cancer, thereby driving their demand and market growth.

Moreover, substantial investments in research and development (R&D) are fueling the ADC market. Pharmaceutical companies, biotechnology firms, and research institutions are investing heavily in the development of new ADCs. These investments are aimed at discovering novel targets, improving drug delivery mechanisms, and enhancing the safety and efficacy of ADCs. The robust pipeline of ADC candidates under clinical trials is a testament to the ongoing R&D efforts, which are expected to yield new and improved therapies.

Additionally, the rising demand for targeted therapies is another crucial factor. Patients and healthcare providers are increasingly favoring treatments that offer precision medicine approaches. ADCs are designed to selectively target and destroy cancer cells while sparing healthy tissues, resulting in fewer side effects compared to traditional chemotherapy. This targeted approach aligns with the growing trend towards personalized medicine, where treatments are tailored to the individual characteristics of each patient’s disease.

Furthermore, regulatory support and approvals from health authorities such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) are propelling the ADC market. These agencies have recognized the potential of ADCs and have provided guidance and incentives for their development and approval. The fast-tracking of ADC approvals and the granting of orphan drug status for certain ADCs indicate strong regulatory backing, which encourages further innovation and investment in this industry.

Segmentation by Product

Kadcyla is the leading segment by Product and held the dominant share in value in 2023. Kadcyla (trastuzumab emtansine) has been a dominant player in the ADC market, especially in the treatment of HER2-positive breast cancer. Its established efficacy and wide use contribute to its significant market share.
The Enhertu segment is expected to exhibit the highest CAGR during the forecast period. Enhertu (trastuzumab deruxtecan) has shown promising clinical outcomes, particularly in HER2-positive breast cancer, and has garnered significant attention and adoption since its approval. Its potent cytotoxic payload and innovative linker technology contribute to its potential as a leading ADC therapy.
Products such as Adcetris, Padcev, Trodelvy, Polivy and others also contribute substantially to the market share.

Segmentation by Disease Type

Breast Cancer is the leading segment by Disease Type and holds a substantial share in 2023. This is primarily due to the prevalence of breast cancer globally and the availability of ADC therapies targeting specific biomarkers associated with this disease, such as HER2.
Blood Cancer are the fastest-growing subsegment during the forecast period. ADC therapies have shown promising results in treating various types of blood cancers, such as Hodgkin’s lymphoma, non-Hodgkin’s lymphoma, and certain types of leukemia. Additionally, ongoing research and development efforts are focusing on expanding the use of ADCs in treating blood cancers, which could drive growth in this subsegment.
Other disease types also contribute substantially to the market share.

Segmentation by Linker Type

Cleavable is the leading segment by Linker Type and holds a substantial share in 2023. Cleavable linkers allow for the release of the cytotoxic payload inside the target cancer cell, enhancing efficacy while minimizing systemic toxicity. This mechanism has been widely studied and implemented in many ADC therapies, contributing to its dominant position in the market.
Non-cleavable linkers is the fastest-growing segment during the forecast period. Non-cleavable linkers offer advantages such as improved stability and simpler manufacturing processes. Additionally, advancements in linker technologies have led to the development of novel non-cleavable linkers with enhanced therapeutic properties, driving their adoption and growth in the market.

Segmentation by Target

The HER2 held the largest market share by target in terms of value in 2023. HER2 is a well-known biomarker associated with various cancers, particularly breast cancer, and ADC therapies targeting HER2, such as Kadcyla (trastuzumab emtansine), have been widely adopted and established in clinical practice.
CD30-targeted ADCs are expected to be the fastest-growing segment during the forecasted period. CD30 is expressed in Hodgkin’s lymphoma and certain types of non-Hodgkin’s lymphoma, presenting a significant opportunity for ADC therapies. ADCs targeting CD30, such as Adcetris (brentuximab vedotin), have demonstrated promising clinical outcomes and are increasingly being used in the treatment of lymphomas, driving growth in this subsegment.
The “Others” segment also witnesses notable growth, particularly as research expands into new targets and indications for ADC therapies.

Segmentation by Payload Type

The MMAE/Auristatin held the largest market share by payload type in terms of value in 2023. Monomethyl auristatin E (MMAE) and auristatin derivatives are commonly used cytotoxic payloads in ADC therapies due to their potent cell-killing activity and proven efficacy in preclinical and clinical studies. Several FDA-approved ADCs, such as Adcetris (brentuximab vedotin) and Polivy (polatuzumab vedotin-piiq), utilize MMAE as their cytotoxic payload, contributing to its dominant position in the market.
Maytansinoids is expected to be the fastest-growing segment during the forecasted period. Maytansinoids are another class of potent cytotoxic agents commonly used in ADC therapies. ADCs containing maytansinoid payloads, such as Kadcyla (trastuzumab emtansine), have demonstrated promising clinical outcomes in various cancer types, particularly breast cancer, driving their adoption and growth in the market.
The “Others” segment also witnesses notable growth, due to continuous research to explore novel cytotoxic payloads with improved therapeutic properties and reduced off-target toxicity.

Segmentation by Region

North America holds the dominant share of the antibody drug conjugate market, driven by the high prevalence of cancer and the increasing adoption of advanced cancer treatment options in the region.
The Asia Pacific region is anticipated to be the fastest-growing market for antibody-drug conjugates, driven by the rising prevalence of cancer and the active development and collaboration of leading players.
The rest of the world, including Latin America, the Middle East, and Africa, supplies the remaining demand for retail inventory management software.

North America holds the dominant share of the antibody drug conjugate market and is expected to maintain its dominance during the forecast period. This dominance is attributed to the high prevalence of cancer and the increasing adoption of advanced cancer treatment options in the region. According to the World Cancer Research Fund International, the United States has the second highest cancer incidence rate globally, with over 1.9 million new cancer cases diagnosed in 2022. This has driven the demand for effective cancer treatments, including antibody drug conjugates (ADCs), which have shown promising results in treating various types of cancer.

Additionally, the strong presence of key ADC manufacturers in North America has also contributed to the region’s market dominance. Major players such as Seagen, Inc., Pfizer, Inc., and Gilead Sciences, Inc. are headquartered in the United States and have a significant share of the global ADC market. These companies have been actively investing in research and development to expand their ADC pipelines, further driving the growth of the market. For instance, in May 2023, Pfizer announced a USD 4.3 billion investment to accelerate its cancer research and development efforts. This investment will fund the expansion of Pfizer’s oncology pipeline and manufacturing capabilities, with a focus on developing innovative cancer treatments, including antibody-drug conjugates (ADCs).

On the other hand, the Asia Pacific region is anticipated to be the fastest-growing market for antibody-drug conjugates during the forecast period. This rapid growth can be attributed to the rising prevalence of cancer in the region, which drives the demand for innovative and effective treatment options. As the number of cancer cases increases, there is a heightened need for targeted therapies such as antibody-drug conjugates, which offer more precise and effective treatment with fewer side effects compared to traditional chemotherapy.

Moreover, the presence of leading players such as Daiichi Sankyo and Takeda Pharmaceutical Company, which are developing numerous products and collaborating to launch new offerings, further boosts the growth of the ADC market. In September 2022, Takeda and Innate Pharma announced a strategic collaboration to discover, develop, and commercialize novel antibody-drug conjugates (ADCs) targeting natural killer (NK) cell receptors for the treatment of solid tumors. Under the agreement, the companies will leverage Innate Pharma’s expertise in NK cell biology and Takeda’s ADC technology platform to generate ADC candidates.

Key Highlights of the Report

The global antibody drug conjugate market is segmented by Product, Disease Type, Linker Type, Target, Payload Type and region. The Kadcyla segment dominated the market in 2023, holding the largest value share. However, Blood Cancer segment is expected to see the fastest growth in terms of disease type, and the HER2 remains the primary Target, with North America leading the market share.

The Antibody Drug Conjugate (ADC) market is growing rapidly due to the rising incidence of cancer. Significant investments in research and development are producing innovative ADCs with better efficacy and safety, driving market growth. Additionally, patients and healthcare providers prefer ADCs for their precision and fewer side effects compared to traditional treatments. Supportive regulatory environments and fast-tracking approvals by health authorities further boost the ADC market, encouraging continued innovation and adoption.

Nonetheless, while North America led growth in the Antibody Drug Conjugate industry in 2023, driven by substantial R&D investment and supportive regulatory frameworks, Asia Pacific is set for the highest forecasted growth, driven by the region’s high prevalence of cancer and increasing healthcare investments.

What Are The Main Drivers Of The Global Antibody Drug Conjugate Market?

The Antibody Drug Conjugate market is growing rapidly due to the rising incidence of cancer. Significant investments in research and development are producing innovative ADCs with better efficacy and safety, driving market growth. Additionally, patients and healthcare providers prefer ADCs for their precision and fewer side effects compared to traditional treatments. Supportive regulatory environments and fast-tracking approvals by health authorities further boost the ADC market, encouraging continued innovation and adoption.

What are The Major Challenges Faced By The Global Antibody Drug Conjugate Market?

The high development costs of Antibody Drug Conjugates (ADCs) significantly restrain market growth. Developing these drugs requires substantial investment in research, clinical trials, and regulatory approvals, creating a financial barrier, especially for smaller companies. Additionally, the manufacturing process is highly complex demanding specialized facilities and expertise. This complexity increases production costs and presents scalability challenges, limiting their widespread adoption.

What Are The Growth Opportunities In The Global Antibody Drug Conjugate Market?

Advancements in biotechnology are creating significant opportunities for Antibody Drug Conjugates (ADCs). Innovations in antibody engineering, linker technologies, and payload selection are enhancing ADC efficacy and safety, broadening their therapeutic applications. Beyond oncology, ADCs are being explored in infectious diseases and as immunomodulatory agents for targeted delivery of anti-inflammatory drugs. Despite development challenges, the success of approved ADCs and a growing pipeline of investigational drugs highlight their potential to improve patient outcomes and expand market opportunities.

Market Drivers

Several factors drive the global antibody drug conjugate Market. The following are the key drivers of the global antibody drug conjugate Market:

Growing Incidence of Cancer Globally

The increasing prevalence of cancer worldwide is a significant driver of the Antibody Drug Conjugate (ADC) market. As the incidence of various cancers rises, there is an urgent need for more effective treatments. According to the International Agency for Research on Cancer (IARC), approximately 20 million cancer cases were newly diagnosed, and 9.7 million people died from the disease worldwide in 2022. This alarming trend is predicted to increase to 35 million new cancer cases by 2050 due to projected population growth.

ADCs represent a promising class of drugs that offer targeted cancer therapy by combining the specificity of antibodies with the potent cell-killing ability of cytotoxic drugs. This dual action allows ADCs to precisely target and destroy cancer cells while minimizing damage to healthy tissues, making them particularly effective in treating various types of cancer. This targeted approach is highly beneficial in managing complex cancer cases and reducing side effects compared to traditional chemotherapy.

The rising demand for ADCs is further supported by regulatory milestones. According to the American Society of Clinical Oncology, as of November 2022, there have been 13 ADCs approved by the U.S. Food and Drug Administration (FDA), many of which are designed to treat “liquid” tumors such as leukemias and lymphomas. These approvals highlight the growing acceptance and recognition of ADCs as a viable and effective treatment option, thus driving their demand and market growth.

Market Restraints

The global antibody drug conjugate market faces some challenges that may hinder its growth. These include the following:

High Development Costs Associated with ADCs

The high development costs associated with Antibody Drug Conjugates (ADCs) are a major restraint on the market’s growth. Developing these sophisticated drugs requires substantial investment in research and development (R&D), clinical trials, and regulatory approvals. The financial burden of these activities is considerable, often acting as a significant barrier, particularly for smaller companies with limited resources. This financial challenge limits the number of new ADCs entering the market, slowing overall market expansion.

Moreover, the manufacturing process for ADCs is highly complex and requires specialized facilities and expertise. The intricate process involves the precise conjugation of antibodies to cytotoxic drugs, a step that must ensure both stability and efficacy of the final product. This complexity increases production costs and also poses significant scalability issues. Specialized equipment and highly trained personnel are essential for manufacturing ADCs that makes the production process expensive and less flexible, hindering the widespread adoption of ADCs.

Opportunities

The global antibody drug conjugate market offers significant growth opportunities. These include the following:

Innovations in Drug Technology

Advancements in biotechnology are creating significant opportunities for the future development of Antibody Drug Conjugates (ADCs). Innovations in antibody engineering, linker technologies, and payload selection are enhancing the efficacy and safety of ADCs, enabling the creation of more effective and targeted therapies. These technological breakthroughs broaden the scope of ADC applications. Additionally, combination therapies integrating ADCs with immunotherapies or other targeted agents could present synergistic effects, amplifying their clinical impact.

For example, ADCs combined with checkpoint inhibitors including PD-1 inhibitors, pembrolizumab and nivolumab, are being explored in various stages of clinical trials. These combinations offer attractive treatment options for frail or elderly patients who are at higher risk of severe toxicity from chemotherapy. Although most oncology trials are still in early phases, the wide range of drug candidates and cancer types being investigated highlights the enormous potential of ADCs.

Moreover, the potential of ADCs extends beyond oncology. The technology is being explored in the fight against infectious diseases and as immunomodulatory agents, enabling the targeted delivery of anti-inflammatory drugs. Despite ongoing challenges and limitations in their development, the success of approved ADCs and the growing pipeline of investigational ADCs demonstrate their potential to meet diverse clinical needs and improve patient outcomes. This expanding versatility and applicability create promising market prospects for ADCs in the future.

Competitive Landscape

Key Players

The global antibody drug conjugate market is highly competitive, with several key players. Some of the major players in the market:

Seagen Inc.
Takeda Pharmaceutical Company Ltd.
AstraZeneca Plc.
F. Hoffmann-La Roche Ltd.
Pfizer Inc.
ImmunoGen Inc.
Gilead Sciences Inc.
Daiichi Sankyo Company Ltd.

These organizations prioritize business expansions, partnerships, and collaborations to stay competitive.

The key players in the global antibody drug conjugate market continually seek to stay ahead through product launches.

In August 2023, Takeda announced an exclusive licensing agreement with ImmunoGen to develop and commercialize mirvetuximab soravtansine-gynx (MIRV) for the treatment of folate receptor-alpha (FRα)-positive ovarian cancer in Japan. MIRV is the first antibody-drug conjugate (ADC) developed for ovarian cancer and was recently granted accelerated approval in the U.S. for platinum-resistant disease.

In March 2022, Sanofi and Seagen Inc. announced an exclusive collaboration agreement to design, develop, and commercialize antibody-drug conjugates (ADCs) for up to three cancer targets. The collaboration will utilize Sanofi’s proprietary monoclonal antibody (mAb) technology and Seagen’s proprietary ADC technology.

How Companies are Performing in the Antibody Drug Conjugate Market?

The global antibody drug conjugate market is highly competitive, with several key players.

Startups are pivotal in propelling the Antibody Drug Conjugates (ADCs) industry forward, bringing fresh perspectives, innovative technologies, and novel solutions to the forefront. These dynamic companies are driving progress in several key areas, from research and development to manufacturing and commercialization, ultimately expanding the therapeutic landscape for cancer and other diseases.

The development of next-generation ADC platforms is a significant contribution to the industry. Companies such as Mersana Therapeutics and ADC Therapeutics are pioneering novel approaches to ADC design, leveraging advanced antibody engineering techniques and innovative linker technologies to enhance drug potency, specificity, and stability. By optimizing the molecular structure of ADCs, these startups aim to overcome existing limitations and unlock new therapeutic possibilities.

Moreover, startups are revolutionizing ADC manufacturing processes, addressing critical challenges related to scalability, cost-efficiency, and product quality. For instance, companies such as CytomX Therapeutics and Synaffix are developing proprietary bioprocessing technologies and bioconjugation methods to streamline ADC production and improve yield and consistency. These innovations ensure the reliable supply of ADC therapies to meet growing clinical demands.

Furthermore, startups are driving innovation in companion diagnostic development for ADCs, enabling personalized treatment approaches based on individual patient characteristics. Examples include Foundation Medicine and Guardant Health, which specialize in developing advanced molecular diagnostic assays to identify biomarkers associated with ADC response and resistance. By integrating companion diagnostics into clinical practice, these startups empower healthcare providers to make informed treatment decisions and optimize patient outcomes. With their agility, creativity, and entrepreneurial spirit, these companies are shaping the future of ADC therapy, bringing us closer to more effective, personalized, and accessible treatments for cancer and other diseases.

Summary of Key Findings

The Antibody Drug Conjugate (ADC) market is growing rapidly due to the rising incidence of cancer. Significant investments in research and development are producing innovative ADCs with better efficacy and safety, driving market growth. Additionally, patients and healthcare providers prefer ADCs for their precision and fewer side effects compared to traditional treatments. Supportive regulatory environments and fast-tracking approvals by health authorities further boost the ADC market, encouraging continued innovation and adoption.

Market segmented by Product, Disease Type, Linker Type, Target, Payload Type and region.
Kadcyla are the most popular product, with the HER2 remaining the primary Target segment.

North America is leading the market share; the market is highly competitive, with key players including Seagen, Inc., (previously Seattle Genetics, Inc.); Takeda Pharmaceutical Company Ltd.; AstraZeneca PLC, F. Hoffmann-La Roche Ltd.; Pfizer, Inc.; ImmunoGen, Inc.; Gilead Sciences, Inc. (acquired Immunomedics); Daiichi Sankyo Company Ltd

Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!

Customize Now

Future Outlook

Positive outlook for the global antibody drug conjugate market with significant growth potential in the North American region.
The key drivers accelerating the growth of the antibody drug conjugate market include the rising prevalence of cancer, significant R&D investments, increased demand for targeted therapies, and supportive regulatory environments.
During the forecast period, high development costs of Antibody Drug Conjugates and complexity in manufacturing processes are expected to restrain the market growth.
Key firms must focus on product innovation, growing market reach, and maintaining competitive pricing to keep ahead of the competition.

How CXOs Can Benefit from the Credence Research Antibody Drug Conjugate Market Report

The Credence Research Antibody Drug Conjugate Market Report provides CXOs with a comprehensive overview of the market, including:

Market size and growth forecast:The report provides detailed estimates of the global antibody drug conjugate market size, segmented by Product, Disease Type, Linker Type, Target, Payload Type and region. It also includes forecasts for the market through 2032 based on key trends and drivers.
Market segmentation:The report segments the antibody drug conjugate market by Product, Disease Type, Linker Type, Target, Payload Type and region. This segmentation provides CXOs with a granular understanding of the market and the opportunities in each segment.
Competitive Landscape:The report profiles the key players in the antibody drug conjugate market and provides insights into their strategies, product offerings, and financial performance. This information can help CXOs to identify and assess their competition.
Key trends and drivers:The report identifies and analyzes the key trends and drivers shaping the Antibody Drug Conjugate Market. This information can help CXOs make informed decisions about their investments and strategies.

CXOs can use the insights from the Credence Research Antibody Drug Conjugate Market Report to:

Identify growth opportunities:The report can help CXOs identify new growth opportunities in the Antibody Drug Conjugate Market. For example, it identifies the rising prevalence of cancer, significant R&D investments, increased demand for targeted therapies, and supportive regulatory environments.
Make informed investment decisions:The report can help CXOs make informed investment decisions about Antibody Drug Conjugate. For example, it provides insights into the key factors to consider when evaluating Antibody Drug Conjugate providers.
Develop competitive strategies:The report can help CXOs develop competitive strategies for their Antibody Drug Conjugate businesses. For example, it identifies the key strategies that Antibody Drug Conjugate providers are using to differentiate themselves from their competitors.
Track market developments:The report can help CXOs monitor market developments and stay ahead of the curve. For example, it provides insights into the latest trends and innovations in the Antibody Drug Conjugate Market.

The Credence Research Antibody Drug Conjugate Market Report is helpful for CXOs who want to learn more about the market and identify potential opportunities.

Segmentation

By Product
- Kadcyla
- Enhertu
- Adcetris
- Padcev
- Trodelvy
- Polivy
- Others
By Disease Type
- Breast Cancer
- Blood Cancer
- Others
By Linker Type
- Non-Cleavable
- Cleavable
By Target
- HER2
- CD22
- CD30
- Others
By Payload Type
- MMAE/Auristatin
- Calicheamicin
- Maytansinoids
- Others
By Region
- North America
  - The U.S
  - Canada
  - Mexico
- Europe
  - Germany
  - France
  - The U.K.
  - Italy
  - Spain
  - Rest of Europe
- Asia Pacific
  - China
  - Japan
  - India
  - South Korea
  - South-east Asia
  - Rest of Asia Pacific
- Latin America
  - Brazil
  - Argentina
  - Rest of Latin America
- Middle East & Africa
  - GCC Countries
  - South Africa
  - Rest of the Middle East and Africa

Adjacent Markets

In the Antibody Drug Conjugate Market, several adjacent markets have high revenue growth opportunities. The key adjacent markets for Antibody Drug Conjugate are-

Adjacent Markets
Monoclonal Antibodies (mAbs) Market	Cancer Immunotherapy Market	Antibody Therapeutics Market
Antibody Discovery Market	Precision Medicine Market	Breast Cancer Therapeutics Market
Cancer Biomarkers Market	Oncology/Cancer Drugs Market	Leukemia Therapeutics Market

1. Preface
1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. USP and Key Offerings
1.2. Research Scope
1.3. Market Introduction
2. Executive Summary
2.1. Market Snapshot: Global Antibody Drug Conjugate Market
2.1.1. Global Antibody Drug Conjugate Market, By Product
2.1.2. Global Antibody Drug Conjugate Market, By Disease Type
2.1.3. Global Antibody Drug Conjugate Market, By Linker Type
2.1.4. Global Antibody Drug Conjugate Market, By Target
2.1.5. Global Antibody Drug Conjugate Market, By Payload Type
2.1.6. Global Antibody Drug Conjugate Market, By Region
2.2. Insights from Primary Respondents
3. Market Dynamics & Factors Analysis
3.1. Introduction
3.1.1. Global Antibody Drug Conjugate Market Value, 2019-2032, (US$ Mn)
3.1.2. Y-o-Y Growth Trend Analysis
3.2. Market Dynamics
3.2.1. Antibody Drug Conjugate Market Drivers
3.2.2. Antibody Drug Conjugate Market Restraints
3.2.3. Antibody Drug Conjugate Market Opportunities
3.2.4. Major Antibody Drug Conjugate Industry Challenges
3.3. Growth and Development Patterns
3.4. Investment Feasibility Analysis
3.5. Market Opportunity Analysis
3.5.1. Product
3.5.2. Disease Type
3.5.3. Linker Type
3.5.4. Target
3.5.5. Payload Type
3.5.6. Geography
4. Market Competitive Landscape Analysis
4.1. Company Market Share Analysis, 2023
4.1.1. Global Antibody Drug Conjugate Market: Company Market Share, Value 2023
4.1.2. Global Antibody Drug Conjugate Market: Top 6 Company Market Share, Value 2023
4.1.3. Global Antibody Drug Conjugate Market: Top 3 Company Market Share, Value 2023
4.2. Global Antibody Drug Conjugate Market: Company Revenue Share Analysis, 2023
4.3. Company Assessment Metrics, 2023
4.3.1. Stars
4.3.2. Emerging Leaders
4.3.3. Pervasive Players
4.3.4. Participants
4.4. Startups/ SMEs Assessment Metrics, 2023
4.4.1. Progressive Companies
4.4.2. Responsive Companies
4.4.3. Dynamic Companies
4.4.4. Starting Blocks
4.5. Strategic Development
4.5.1. Acquisition and Mergers
4.5.2. New Product Launch
4.5.3. Regional Expansion
4.5.4. Partnerships
4.6. Key Player Product Matrix
4.7. Potential for New Players in the Global Antibody Drug Conjugate Market
5. Premium Insights
5.1. STAR (Situation, Task, Action, Results) Analysis
5.2. Porter’s Five Forces Analysis
5.2.1. Threat of New Entrants
5.2.2. Bargaining Power of Buyers/Consumers
5.2.3. Bargaining Power of Suppliers
5.2.4. Threat of Substitute Types
5.2.5. Intensity of Competitive Rivalry
5.3. PESTEL Analysis
5.3.1. Political Factors
5.3.2. Economic Factors
5.3.3. Social Factors
5.3.4. Technological Factors
5.3.5. Environmental Factors
5.3.6. Legal Factors
5.4. Key Market Trends
5.4.1. Demand Side Trends
5.4.2. Supply Side Trends
5.5. Value Chain Analysis
5.6. Technology Analysis
5.6.1. Research and development in the global market
5.6.2. Patent Analysis
5.6.3. Emerging technologies and their potential disruption to the market
5.7. Consumer Behaviour Analysis
5.7.1. Consumer Preferences and Expectations
5.7.2. Factors Influencing Consumer Buying Decisions
5.7.2.1. North America
5.7.2.2. Europe
5.7.2.3. Asia Pacific
5.7.2.4. Latin America
5.7.2.5. Middle East and Africa
5.7.3. Consumer Pain Points
5.8. Analysis and Recommendations
5.9. Adjacent Market Analysis
6. Market Positioning of Key Players, 2023
6.1. Company market share of key players, 2023
6.2. Competitive Benchmarking
6.3. Market Positioning of Key Vendors
6.4. Geographical Presence Analysis
6.5. Major Strategies Adopted by Key Players
6.5.1. Key Strategies Analysis
6.5.2. Mergers and Acquisitions
6.5.3. Partnerships
6.5.4. Product Launch
6.5.5. Geographical Expansion
6.5.6. Others
7. Impact Analysis of COVID 19 and Russia – Ukraine War on Antibody Drug Conjugate Market
7.1. Ukraine-Russia War Impact
7.1.1. Uncertainty and Economic Instability
7.1.2. Supply chain disruptions
7.1.3. Regional market shifts
7.1.4. Shift in government priorities
7.2. COVID-19 Impact Analysis
7.2.1. Supply Chain Disruptions
7.2.2. Demand Fluctuations
7.2.3. Shift in Product Mix
7.2.4. Reduced Industrial Activity
7.2.5. Regional Impact Analysis
7.2.5.1. North America
7.2.5.2. Europe
7.2.5.3. Asia Pacific
7.2.5.4. Latin America
7.2.5.5. Middle East and Africa
8. Global Antibody Drug Conjugate Market, By Product
8.1. Global Antibody Drug Conjugate Market Overview, by Product
8.1.1. Global Antibody Drug Conjugate Market Revenue Share, By Product, 2023 Vs 2032 (in %)
8.2. Kadcyla
8.2.1. Global Antibody Drug Conjugate Market, By Kadcyla, By Region, 2019-2032 (US$ Mn)
8.2.2. Market Dynamics for Kadcyla
8.2.2.1. Drivers
8.2.2.2. Restraints
8.2.2.3. Opportunities
8.2.2.4. Trends
8.3. Enhertu
8.3.1. Global Antibody Drug Conjugate Market, By Enhertu, By Region, 2019-2032 (US$ Mn)
8.3.2. Market Dynamics for Enhertu
8.3.2.1. Drivers
8.3.2.2. Restraints
8.3.2.3. Opportunities
8.3.2.4. Trends
8.4. Adcetris
8.4.1. Global Antibody Drug Conjugate Market, By Adcetris, By Region, 2019-2032 (US$ Mn)
8.4.2. Market Dynamics for Adcetris
8.4.2.1. Drivers
8.4.2.2. Restraints
8.4.2.3. Opportunities
8.4.2.4. Trends
8.5. Padcev
8.5.1. Global Antibody Drug Conjugate Market, By Padcev, By Region, 2019-2032 (US$ Mn)
8.5.2. Market Dynamics for Padcev
8.5.2.1. Drivers
8.5.2.2. Restraints
8.5.2.3. Opportunities
8.5.2.4. Trends
8.6. Trodelvy
8.6.1. Global Antibody Drug Conjugate Market, By Trodelvy, By Region, 2019-2032 (US$ Mn)
8.6.2. Market Dynamics for Trodelvy
8.6.2.1. Drivers
8.6.2.2. Restraints
8.6.2.3. Opportunities
8.6.2.4. Trends
8.7. Polivy
8.7.1. Global Antibody Drug Conjugate Market, By Polivy, By Region, 2019-2032 (US$ Mn)
8.7.2. Market Dynamics for Polivy
8.7.2.1. Drivers
8.7.2.2. Restraints
8.7.2.3. Opportunities
8.7.2.4. Trends
8.8. Others
8.8.1. Global Antibody Drug Conjugate Market, By Others, By Region, 2019-2032 (US$ Mn)
8.8.2. Market Dynamics for Others
8.8.2.1. Drivers
8.8.2.2. Restraints
8.8.2.3. Opportunities
8.8.2.4. Trends
9. Global Antibody Drug Conjugate Market, By Disease Type
9.1. Global Antibody Drug Conjugate Market Overview, by Disease Type
9.1.1. Global Antibody Drug Conjugate Market Revenue Share, By Disease Type, 2023 Vs 2032 (in %)
9.2. Breast Cancer
9.2.1. Global Antibody Drug Conjugate Market, By Breast Cancer, By Region, 2019-2032 (US$ Mn)
9.2.2. Market Dynamics for Breast Cancer
9.2.2.1. Drivers
9.2.2.2. Restraints
9.2.2.3. Opportunities
9.2.2.4. Trends
9.3. Blood Cancer
9.3.1. Global Antibody Drug Conjugate Market, By Blood Cancer, By Region, 2019-2032 (US$ Mn)
9.3.2. Market Dynamics for Blood Cancer
9.3.2.1. Drivers
9.3.2.2. Restraints
9.3.2.3. Opportunities
9.3.2.4. Trends
9.4. Others
9.4.1. Global Antibody Drug Conjugate Market, By Others, By Region, 2019-2032 (US$ Mn)
9.4.2. Market Dynamics for Others
9.4.2.1. Drivers
9.4.2.2. Restraints
9.4.2.3. Opportunities
9.4.2.4. Trends
10. Global Antibody Drug Conjugate Market, By Linker Type
10.1. Global Antibody Drug Conjugate Market Overview, By Linker Type
10.1.1. Global Antibody Drug Conjugate Market Revenue Share, By Linker Type, 2023 Vs 2032 (in %)
10.2. Non-Cleavable
10.2.1. Global Antibody Drug Conjugate Market, By Non-Cleavable, By Region, 2019-2032 (US$ Mn)
10.2.2. Market Dynamics for Non-Cleavable
10.2.2.1. Drivers
10.2.2.2. Restraints
10.2.2.3. Opportunities
10.2.2.4. Trends
10.3. Cleavable
10.3.1. Global Antibody Drug Conjugate Market, By Cleavable, By Region, 2019-2032 (US$ Mn)
10.3.2. Market Dynamics for Cleavable
10.3.2.1. Drivers
10.3.2.2. Restraints
10.3.2.3. Opportunities
10.3.2.4. Trends
11. Global Antibody Drug Conjugate Market, By Target
11.1. Global Antibody Drug Conjugate Market Overview, by Target
11.1.1. Global Antibody Drug Conjugate Market Revenue Share, By Target, 2023 Vs 2032 (in %)
11.2. HER2
11.2.1. Global Antibody Drug Conjugate Market, By HER2, By Region, 2019-2032 (US$ Mn)
11.2.2. Market Dynamics for HER2
11.2.2.1. Drivers
11.2.2.2. Restraints
11.2.2.3. Opportunities
11.2.2.4. Trends
11.3. CD22
11.3.1. Global Antibody Drug Conjugate Market, By CD22, By Region, 2019-2032 (US$ Mn)
11.3.2. Market Dynamics for CD22
11.3.2.1. Drivers
11.3.2.2. Restraints
11.3.2.3. Opportunities
11.3.2.4. Trends
11.4. CD30
11.4.1. Global Antibody Drug Conjugate Market, By CD30, By Region, 2019-2032 (US$ Mn)
11.4.2. Market Dynamics for CD30
11.4.2.1. Drivers
11.4.2.2. Restraints
11.4.2.3. Opportunities
11.4.2.4. Trends
11.5. Others
11.5.1. Global Antibody Drug Conjugate Market, By Others, By Region, 2019-2032 (US$ Mn)
11.5.2. Market Dynamics for Others
11.5.2.1. Drivers
11.5.2.2. Restraints
11.5.2.3. Opportunities
11.5.2.4. Trends
12. Global Antibody Drug Conjugate Market, By Payload Type
12.1. Global Antibody Drug Conjugate Market Overview, by Payload Type
12.1.1. Global Antibody Drug Conjugate Market Revenue Share, By Payload Type, 2023 Vs 2032 (in %)
12.2. MMAE/Auristatin
12.2.1. Global Antibody Drug Conjugate Market, By MMAE/Auristatin, By Region, 2019-2032 (US$ Mn)
12.2.2. Market Dynamics for MMAE/Auristatin
12.2.2.1. Drivers
12.2.2.2. Restraints
12.2.2.3. Opportunities
12.2.2.4. Trends
12.3. Calicheamicin
12.3.1. Global Antibody Drug Conjugate Market, By Calicheamicin, By Region, 2019-2032 (US$ Mn)
12.3.2. Market Dynamics for Calicheamicin
12.3.2.1. Drivers
12.3.2.2. Restraints
12.3.2.3. Opportunities
12.3.2.4. Trends
12.4. Maytansinoids
12.4.1. Global Antibody Drug Conjugate Market, By Maytansinoids, By Region, 2019-2032 (US$ Mn)
12.4.2. Market Dynamics for Maytansinoids
12.4.2.1. Drivers
12.4.2.2. Restraints
12.4.2.3. Opportunities
12.4.2.4. Trends
12.5. Others
12.5.1. Global Antibody Drug Conjugate Market, By Others, By Region, 2019-2032 (US$ Mn)
12.5.2. Market Dynamics for Others
12.5.2.1. Drivers
12.5.2.2. Restraints
12.5.2.3. Opportunities
12.5.2.4. Trends
13. Global Antibody Drug Conjugate Market, By Region
13.1. Global Antibody Drug Conjugate Market Overview, by Region
13.1.1. Global Antibody Drug Conjugate Market, By Region, 2023 vs 2032 (in%)
13.2. Product
13.2.1. Global Antibody Drug Conjugate Market, By Product, 2019-2032 (US$ Mn)
13.3. Disease Type
13.3.1. Global Antibody Drug Conjugate Market, By Disease Type, 2019-2032 (US$ Mn)
13.4. Linker Type
13.4.1. Global Antibody Drug Conjugate Market, By Linker Type, 2019-2032 (US$ Mn)
13.5. Target
13.5.1. Global Antibody Drug Conjugate Market, By Target, 2019-2032 (US$ Mn)
13.6. Payload Type
13.6.1. Global Antibody Drug Conjugate Market, By Payload Type, 2019-2032 (US$ Mn)
14. North America Antibody Drug Conjugate Market Analysis
14.1. Overview
14.1.1. Market Dynamics for North America
14.1.1.1. Drivers
14.1.1.2. Restraints
14.1.1.3. Opportunities
14.1.1.4. Trends
14.2. North America Antibody Drug Conjugate Market, by Product, 2019-2032(US$ Mn)
14.2.1. Overview
14.2.2. SRC Analysis
14.3. North America Antibody Drug Conjugate Market, by Disease Type, 2019-2032(US$ Mn)
14.3.1. Overview
14.3.2. SRC Analysis
14.4. North America Antibody Drug Conjugate Market, By Linker Type, 2019-2032(US$ Mn)
14.4.1. Overview
14.4.2. SRC Analysis
14.5. North America Antibody Drug Conjugate Market, by Target, 2019-2032(US$ Mn)
14.5.1. Overview
14.5.2. SRC Analysis
14.6. North America Antibody Drug Conjugate Market, by Payload Type, 2019-2032(US$ Mn)
14.6.1. Overview
14.6.2. SRC Analysis
14.7. North America Antibody Drug Conjugate Market, by Country, 2019-2032 (US$ Mn)
14.7.1. North America Antibody Drug Conjugate Market, by Country, 2023 Vs 2032 (in%)
14.7.2. U.S.
14.7.3. Canada
14.7.4. Mexico
15. Europe Antibody Drug Conjugate Market Analysis
15.1. Overview
15.1.1. Market Dynamics for Europe
15.1.1.1. Drivers
15.1.1.2. Restraints
15.1.1.3. Opportunities
15.1.1.4. Trends
15.2. Europe Antibody Drug Conjugate Market, by Product, 2019-2032(US$ Mn)
15.2.1. Overview
15.2.2. SRC Analysis
15.3. Europe Antibody Drug Conjugate Market, by Disease Type, 2019-2032(US$ Mn)
15.3.1. Overview
15.3.2. SRC Analysis
15.4. Europe Antibody Drug Conjugate Market, By Linker Type, 2019-2032(US$ Mn)
15.4.1. Overview
15.4.2. SRC Analysis
15.5. Europe Antibody Drug Conjugate Market, by Target, 2019-2032(US$ Mn)
15.5.1. Overview
15.5.2. SRC Analysis
15.6. Europe Antibody Drug Conjugate Market, by Payload Type, 2019-2032(US$ Mn)
15.6.1. Overview
15.6.2. SRC Analysis
15.7. Europe Antibody Drug Conjugate Market, by Country, 2019-2032 (US$ Mn)
15.7.1. Europe Antibody Drug Conjugate Market, by Country, 2023 Vs 2032 (in%)
15.7.2. UK
15.7.3. France
15.7.4. Germany
15.7.5. Italy
15.7.6. Spain
15.7.7. Benelux
15.7.8. Russia
15.7.9. Rest of Europe
16. Asia Pacific Antibody Drug Conjugate Market Analysis
16.1. Overview
16.1.1. Market Dynamics for Asia Pacific
16.1.1.1. Drivers
16.1.1.2. Restraints
16.1.1.3. Opportunities
16.1.1.4. Trends
16.2. Asia Pacific Antibody Drug Conjugate Market, by Product, 2019-2032(US$ Mn)
16.2.1. Overview
16.2.2. SRC Analysis
16.3. Asia Pacific Antibody Drug Conjugate Market, by Disease Type, 2019-2032(US$ Mn)
16.3.1. Overview
16.3.2. SRC Analysis
16.4. Asia Pacific Antibody Drug Conjugate Market, By Linker Type, 2019-2032(US$ Mn)
16.4.1. Overview
16.4.2. SRC Analysis
16.5. Asia Pacific Antibody Drug Conjugate Market, by Target, 2019-2032(US$ Mn)
16.5.1. Overview
16.5.2. SRC Analysis
16.6. Asia Pacific Antibody Drug Conjugate Market, by Payload Type, 2019-2032(US$ Mn)
16.6.1. Overview
16.6.2. SRC Analysis
16.7. Asia Pacific Antibody Drug Conjugate Market, by Country, 2019-2032 (US$ Mn)
16.7.1. Asia Pacific Antibody Drug Conjugate Market, by Country, 2023 Vs 2032 (in%)
16.7.2. China
16.7.3. Japan
16.7.4. India
16.7.5. South Korea
16.7.6. South East Asia
16.7.7. Rest of Asia Pacific
17. Latin America Antibody Drug Conjugate Market Analysis
17.1. Overview
17.1.1. Market Dynamics for Latin America
17.1.1.1. Drivers
17.1.1.2. Restraints
17.1.1.3. Opportunities
17.1.1.4. Trends
17.2. Latin America Antibody Drug Conjugate Market, by Product, 2019-2032(US$ Mn)
17.2.1. Overview
17.2.2. SRC Analysis
17.3. Latin America Antibody Drug Conjugate Market, by Disease Type, 2019-2032(US$ Mn)
17.3.1. Overview
17.3.2. SRC Analysis
17.4. Latin America Antibody Drug Conjugate Market, By Linker Type, 2019-2032(US$ Mn)
17.4.1. Overview
17.4.2. SRC Analysis
17.5. Latin America Antibody Drug Conjugate Market, by Target, 2019-2032(US$ Mn)
17.5.1. Overview
17.5.2. SRC Analysis
17.6. Latin America Antibody Drug Conjugate Market, by Payload Type, 2019-2032(US$ Mn)
17.6.1. Overview
17.6.2. SRC Analysis
17.7. Latin America Antibody Drug Conjugate Market, by Country, 2019-2032 (US$ Mn)
17.7.1. Latin America Antibody Drug Conjugate Market, by Country, 2023 Vs 2032 (in%)
17.7.2. Brazil
17.7.3. Argentina
17.7.4. Rest of Latin America
18. Middle East Antibody Drug Conjugate Market Analysis
18.1. Overview
18.1.1. Market Dynamics for Middle East
18.1.1.1. Drivers
18.1.1.2. Restraints
18.1.1.3. Opportunities
18.1.1.4. Trends
18.2. Middle East Antibody Drug Conjugate Market, by Product, 2019-2032(US$ Mn)
18.2.1. Overview
18.2.2. SRC Analysis
18.3. Middle East Antibody Drug Conjugate Market, by Disease Type, 2019-2032(US$ Mn)
18.3.1. Overview
18.3.2. SRC Analysis
18.4. Middle East Antibody Drug Conjugate Market, By Linker Type, 2019-2032(US$ Mn)
18.4.1. Overview
18.4.2. SRC Analysis
18.5. Middle East Antibody Drug Conjugate Market, by Target, 2019-2032(US$ Mn)
18.5.1. Overview
18.5.2. SRC Analysis
18.6. Middle East Antibody Drug Conjugate Market, by Payload Type, 2019-2032(US$ Mn)
18.6.1. Overview
18.6.2. SRC Analysis
18.7. Middle East Antibody Drug Conjugate Market, by Country, 2019-2032 (US$ Mn)
18.7.1. Middle East Antibody Drug Conjugate Market, by Country, 2023 Vs 2032 (in%)
18.7.2. UAE
18.7.3. Saudi Arabia
18.7.4. Rest of Middle East
19. Africa Antibody Drug Conjugate Market Analysis
19.1. Overview
19.1.1. Market Dynamics for Africa
19.1.1.1. Drivers
19.1.1.2. Restraints
19.1.1.3. Opportunities
19.1.1.4. Trends
19.2. Africa Antibody Drug Conjugate Market, by Product, 2019-2032(US$ Mn)
19.2.1. Overview
19.2.2. SRC Analysis
19.3. Africa Antibody Drug Conjugate Market, by Disease Type, 2019-2032(US$ Mn)
19.3.1. Overview
19.3.2. SRC Analysis
19.4. Africa Antibody Drug Conjugate Market, By Linker Type, 2019-2032(US$ Mn)
19.4.1. Overview
19.4.2. SRC Analysis
19.5. Africa Antibody Drug Conjugate Market, by Target, 2019-2032(US$ Mn)
19.5.1. Overview
19.5.2. SRC Analysis
19.6. Africa Antibody Drug Conjugate Market, by Payload Type, 2019-2032(US$ Mn)
19.6.1. Overview
19.6.2. SRC Analysis
19.7. Africa Antibody Drug Conjugate Market, by Country, 2019-2032 (US$ Mn)
19.7.1. Middle East Antibody Drug Conjugate Market, by Country, 2023 Vs 2032 (in%)
19.7.2. South Africa
19.7.3. Egypt
19.7.4. Rest of Africa
20. Company Profiles
20.1. Seagen Inc.
20.1.1. Company Overview
20.1.2. Products/Services Portfolio
20.1.3. Geographical Presence
20.1.4. SWOT Analysis
20.1.5. Financial Summary
20.1.5.1. Market Revenue and Net Profit (2019-2023)
20.1.5.2. Business Segment Revenue Analysis
20.1.5.3. Geographical Revenue Analysis
20.2. Takeda Pharmaceutical Company Ltd.
20.3. AstraZeneca Plc.
20.4. F. Hoffmann-La Roche Ltd.
20.5. Pfizer Inc.
20.6. ImmunoGen Inc.
20.7. Gilead Sciences Inc.
20.8. Daiichi Sankyo Company Ltd.
21. Research Methodology
21.1. Research Methodology
21.2. Phase I – Secondary Research
21.3. Phase II – Data Modelling
21.3.1. Company Share Analysis Model
21.3.2. Revenue Based Modelling
21.4. Phase III – Primary Research
21.5. Research Limitations
21.5.1. Assumptions

List of Figures
FIG. 1 Global Antibody Drug Conjugate Market: Research Methodology
FIG. 2 Market Size Estimation – Top Down & Bottom up Approach
FIG. 3 Global Antibody Drug Conjugate Market Segmentation
FIG. 4 Global Antibody Drug Conjugate Market, by Product, 2023 (US$ Mn)
FIG. 5 Global Antibody Drug Conjugate Market, by Disease Type, 2023 (US$ Mn)
FIG. 6 Global Antibody Drug Conjugate Market, By Linker Type, 2023 (US$ Mn)
FIG. 7 Global Antibody Drug Conjugate Market, by Target, 2023 (US$ Mn)
FIG. 8 Global Antibody Drug Conjugate Market, by Payload Type, 2023 (US$ Mn)
FIG. 9 Global Antibody Drug Conjugate Market, by Geography, 2023 (US$ Mn)
FIG. 10 Attractive Investment Proposition, by Product, 2023
FIG. 11 Attractive Investment Proposition, by Disease Type, 2023
FIG. 12 Attractive Investment Proposition, By Linker Type, 2023
FIG. 13 Attractive Investment Proposition, by Target, 2023
FIG. 14 Attractive Investment Proposition, by Payload Type, 2023
FIG. 15 Attractive Investment Proposition, by Geography, 2023
FIG. 16 Global Market Share Analysis of Key Antibody Drug Conjugate Market Manufacturers, 2023
FIG. 17 Global Market Positioning of Key Antibody Drug Conjugate Market Manufacturers, 2023
FIG. 18 Global Antibody Drug Conjugate Market Value Contribution, By Product, 2023 & 2032 (Value %)
FIG. 19 Global Antibody Drug Conjugate Market, by Kadcyla, Value, 2019-2032 (US$ Mn)
FIG. 20 Global Antibody Drug Conjugate Market, by Enhertu, Value, 2019-2032 (US$ Mn)
FIG. 21 Global Antibody Drug Conjugate Market, by Adcetris, Value, 2019-2032 (US$ Mn)
FIG. 22 Global Antibody Drug Conjugate Market, by Padcev, Value, 2019-2032 (US$ Mn)
FIG. 23 Global Antibody Drug Conjugate Market, by Trodelvy, Value, 2019-2032 (US$ Mn)
FIG. 24 Global Antibody Drug Conjugate Market, by Polivy, Value, 2019-2032 (US$ Mn)
FIG. 25 Global Antibody Drug Conjugate Market, by Others, Value, 2019-2032 (US$ Mn)
FIG. 26 Global Antibody Drug Conjugate Market Value Contribution, By Disease Type, 2023 & 2032 (Value %)
FIG. 27 Global Antibody Drug Conjugate Market, by Breast Cancer, Value, 2019-2032 (US$ Mn)
FIG. 28 Global Antibody Drug Conjugate Market, by Blood Cancer, Value, 2019-2032 (US$ Mn)
FIG. 29 Global Antibody Drug Conjugate Market, by Others, Value, 2019-2032 (US$ Mn)
FIG. 30 Global Antibody Drug Conjugate Market Value Contribution, By Linker Type, 2023 & 2032 (Value %)
FIG. 31 Global Antibody Drug Conjugate Market, by Non-Cleavable, Value, 2019-2032 (US$ Mn)
FIG. 32 Global Antibody Drug Conjugate Market, by Cleavable, Value, 2019-2032 (US$ Mn)
FIG. 33 Global Antibody Drug Conjugate Market Value Contribution, By Target, 2023 & 2032 (Value %)
FIG. 34 Global Antibody Drug Conjugate Market, by HER2, Value, 2019-2032 (US$ Mn)
FIG. 35 Global Antibody Drug Conjugate Market, by CD22, Value, 2019-2032 (US$ Mn)
FIG. 36 Global Antibody Drug Conjugate Market, by CD30, Value, 2019-2032 (US$ Mn)
FIG. 37 Global Antibody Drug Conjugate Market, by Others, Value, 2019-2032 (US$ Mn)
FIG. 38 Global Antibody Drug Conjugate Market Value Contribution, By Payload Type, 2023 & 2032 (Value %)
FIG. 39 Global Antibody Drug Conjugate Market, by MMAE/Auristatin, Value, 2019-2032 (US$ Mn)
FIG. 40 Global Antibody Drug Conjugate Market, by Calicheamicin, Value, 2019-2032 (US$ Mn)
FIG. 41 Global Antibody Drug Conjugate Market, by Maytansinoids, Value, 2019-2032 (US$ Mn)
FIG. 42 North America Antibody Drug Conjugate Market, 2019-2032 (US$ Mn)
FIG. 43 U.S. Antibody Drug Conjugate Market, 2019-2032 (US$ Mn)
FIG. 44 Canada Antibody Drug Conjugate Market, 2019-2032 (US$ Mn)
FIG. 45 Mexico Antibody Drug Conjugate Market, 2019-2032 (US$ Mn)
FIG. 46 Europe Antibody Drug Conjugate Market, 2019-2032 (US$ Mn)
FIG. 47 Germany Antibody Drug Conjugate Market, 2019-2032 (US$ Mn)
FIG. 48 France Antibody Drug Conjugate Market, 2019-2032 (US$ Mn)
FIG. 49 U.K. Antibody Drug Conjugate Market, 2019-2032 (US$ Mn)
FIG. 50 Italy Antibody Drug Conjugate Market, 2019-2032 (US$ Mn)
FIG. 51 Spain Antibody Drug Conjugate Market, 2019-2032 (US$ Mn)
FIG. 52 Benelux Antibody Drug Conjugate Market, 2019-2032 (US$ Mn)
FIG. 53 Russia Antibody Drug Conjugate Market, 2019-2032 (US$ Mn)
FIG. 54 Rest of Europe Antibody Drug Conjugate Market, 2019-2032 (US$ Mn)
FIG. 55 Asia Pacific Antibody Drug Conjugate Market, 2019-2032 (US$ Mn)
FIG. 56 China Antibody Drug Conjugate Market, 2019-2032 (US$ Mn)
FIG. 57 Japan Antibody Drug Conjugate Market, 2019-2032 (US$ Mn)
FIG. 58 India Antibody Drug Conjugate Market, 2019-2032 (US$ Mn)
FIG. 59 South Korea Antibody Drug Conjugate Market, 2019-2032 (US$ Mn)
FIG. 60 South-East Asia Antibody Drug Conjugate Market, 2019-2032 (US$ Mn)
FIG. 61 Rest of Asia Pacific Antibody Drug Conjugate Market, 2019-2032 (US$ Mn)
FIG. 62 Latin America Antibody Drug Conjugate Market, 2019-2032 (US$ Mn)
FIG. 63 Brazil Antibody Drug Conjugate Market, 2019-2032 (US$ Mn)
FIG. 64 Argentina Antibody Drug Conjugate Market, 2019-2032 (US$ Mn)
FIG. 65 Rest of Latin America Antibody Drug Conjugate Market, 2019-2032 (US$ Mn)
FIG. 66 Middle East Antibody Drug Conjugate Market, 2019-2032 (US$ Mn)
FIG. 67 UAE Antibody Drug Conjugate Market, 2019-2032 (US$ Mn)
FIG. 68 Saudi Arabia Antibody Drug Conjugate Market, 2019-2032 (US$ Mn)
FIG. 69 Rest of Middle East Antibody Drug Conjugate Market, 2019-2032 (US$ Mn)
FIG. 70 Africa Antibody Drug Conjugate Market, 2019-2032 (US$ Mn)
FIG. 71 South Africa Antibody Drug Conjugate Market, 2019-2032 (US$ Mn)
FIG. 72 Egypt Antibody Drug Conjugate Market, 2019-2032 (US$ Mn)
FIG. 73 Rest of Africa Antibody Drug Conjugate Market, 2019-2032 (US$ Mn)

List of Tables
TABLE 1 Market Snapshot: Global Antibody Drug Conjugate Market
TABLE 2 Global Antibody Drug Conjugate Market: Market Drivers Impact Analysis
TABLE 3 Global Antibody Drug Conjugate Market: Market Restraints Impact Analysis
TABLE 4 Global Antibody Drug Conjugate Market, by Competitive Benchmarking, 2023
TABLE 5 Global Antibody Drug Conjugate Market, by Geographical Presence Analysis, 2023
TABLE 6 Global Antibody Drug Conjugate Market, by Key Strategies Analysis, 2023
TABLE 7 Global Antibody Drug Conjugate Market, by Kadcyla, By Region, 2019-2023 (US$ Mn)
TABLE 8 Global Antibody Drug Conjugate Market, by Kadcyla, By Region, 2024-2032 (US$ Mn)
TABLE 9 Global Antibody Drug Conjugate Market, by Enhertu, By Region, 2019-2023 (US$ Mn)
TABLE 10 Global Antibody Drug Conjugate Market, by Enhertu, By Region, 2024-2032 (US$ Mn)
TABLE 11 Global Antibody Drug Conjugate Market, by Adcetris, By Region, 2019-2023 (US$ Mn)
TABLE 12 Global Antibody Drug Conjugate Market, by Adcetris, By Region, 2024-2032 (US$ Mn)
TABLE 13 Global Antibody Drug Conjugate Market, by Padcev, By Region, 2019-2023 (US$ Mn)
TABLE 14 Global Antibody Drug Conjugate Market, by Padcev, By Region, 2024-2032 (US$ Mn)
TABLE 15 Global Antibody Drug Conjugate Market, by Trodelvy, By Region, 2019-2023 (US$ Mn)
TABLE 16 Global Antibody Drug Conjugate Market, by Trodelvy, By Region, 2024-2032 (US$ Mn)
TABLE 17 Global Antibody Drug Conjugate Market, by Polivy, By Region, 2019-2023 (US$ Mn)
TABLE 18 Global Antibody Drug Conjugate Market, by Polivy, By Region, 2024-2032 (US$ Mn)
TABLE 19 Global Antibody Drug Conjugate Market, by Others, By Region, 2019-2023 (US$ Mn)
TABLE 20 Global Antibody Drug Conjugate Market, by Others, By Region, 2024-2032 (US$ Mn)
TABLE 21 Global Antibody Drug Conjugate Market, by Breast Cancer, By Region, 2019-2023 (US$ Mn)
TABLE 22 Global Antibody Drug Conjugate Market, by Breast Cancer, By Region, 2024-2032 (US$ Mn)
TABLE 23 Global Antibody Drug Conjugate Market, by Blood Cancer, By Region, 2019-2023 (US$ Mn)
TABLE 24 Global Antibody Drug Conjugate Market, by Blood Cancer, By Region, 2024-2032 (US$ Mn)
TABLE 25 Global Antibody Drug Conjugate Market, by Others, By Region, 2019-2023 (US$ Mn)
TABLE 26 Global Antibody Drug Conjugate Market, by Others, By Region, 2024-2032 (US$ Mn)
TABLE 27 Global Antibody Drug Conjugate Market, by Non-Cleavable, By Region, 2019-2023 (US$ Mn)
TABLE 28 Global Antibody Drug Conjugate Market, by Non-Cleavable, By Region, 2024-2032 (US$ Mn)
TABLE 29 Global Antibody Drug Conjugate Market, by Cleavable, By Region, 2019-2023 (US$ Mn)
TABLE 30 Global Antibody Drug Conjugate Market, by Cleavable, By Region, 2024-2032 (US$ Mn)
TABLE 31 Global Antibody Drug Conjugate Market, by HER2, By Region, 2019-2023 (US$ Mn)
TABLE 32 Global Antibody Drug Conjugate Market, by HER2, By Region, 2024-2032 (US$ Mn)
TABLE 33 Global Antibody Drug Conjugate Market, by CD22, By Region, 2019-2023 (US$ Mn)
TABLE 34 Global Antibody Drug Conjugate Market, by CD22, By Region, 2024-2032 (US$ Mn)
TABLE 35 Global Antibody Drug Conjugate Market, by CD30, By Region, 2019-2023 (US$ Mn)
TABLE 36 Global Antibody Drug Conjugate Market, by CD30, By Region, 2024-2032 (US$ Mn)
TABLE 37 Global Antibody Drug Conjugate Market, by Others, By Region, 2019-2023 (US$ Mn)
TABLE 38 Global Antibody Drug Conjugate Market, by Others, By Region, 2024-2032 (US$ Mn)
TABLE 39 Global Antibody Drug Conjugate Market, by MMAE/Auristatin, By Region, 2019-2023 (US$ Mn)
TABLE 40 Global Antibody Drug Conjugate Market, by MMAE/Auristatin, By Region, 2024-2032 (US$ Mn)
TABLE 41 Global Antibody Drug Conjugate Market, by Calicheamicin, By Region, 2019-2023 (US$ Mn)
TABLE 42 Global Antibody Drug Conjugate Market, by Calicheamicin, By Region, 2024-2032 (US$ Mn)
TABLE 43 Global Antibody Drug Conjugate Market, by Maytansinoids, By Region, 2019-2023 (US$ Mn)
TABLE 44 Global Antibody Drug Conjugate Market, by Maytansinoids, By Region, 2024-2032 (US$ Mn)
TABLE 45 Global Antibody Drug Conjugate Market, by Others, By Region, 2019-2023 (US$ Mn)
TABLE 46 Global Antibody Drug Conjugate Market, by Others, By Region, 2024-2032 (US$ Mn)
TABLE 47 Global Antibody Drug Conjugate Market, by Product, 2019-2023 (US$ Mn)
TABLE 48 Global Antibody Drug Conjugate Market, by Product, 2024-2032 (US$ Mn)
TABLE 49 Global Antibody Drug Conjugate Market, by Disease Type, 2019-2023 (US$ Mn)
TABLE 50 Global Antibody Drug Conjugate Market, by Disease Type, 2024-2032 (US$ Mn)
TABLE 51 Global Antibody Drug Conjugate Market, By Linker Type, 2019-2023 (US$ Mn)
TABLE 52 Global Antibody Drug Conjugate Market, By Linker Type, 2024-2032 (US$ Mn)
TABLE 53 Global Antibody Drug Conjugate Market, by Target, 2019-2023 (US$ Mn)
TABLE 54 Global Antibody Drug Conjugate Market, by Target, 2024-2032 (US$ Mn)
TABLE 55 Global Antibody Drug Conjugate Market, by Payload Type, 2019-2023 (US$ Mn)
TABLE 56 Global Antibody Drug Conjugate Market, by Payload Type, 2024-2032 (US$ Mn)
TABLE 57 Global Antibody Drug Conjugate Market, by Region, 2019-2023 (US$ Mn)
TABLE 58 Global Antibody Drug Conjugate Market, by Region, 2024-2032 (US$ Mn)
TABLE 59 North America Antibody Drug Conjugate Market, by Product, 2019-2023 (US$ Mn)
TABLE 60 North America Antibody Drug Conjugate Market, by Product, 2024-2032 (US$ Mn)
TABLE 61 North America Antibody Drug Conjugate Market, by Disease Type, 2019-2023 (US$ Mn)
TABLE 62 North America Antibody Drug Conjugate Market, by Disease Type, 2024-2032 (US$ Mn)
TABLE 63 North America Antibody Drug Conjugate Market, By Linker Type, 2019-2023 (US$ Mn)
TABLE 64 North America Antibody Drug Conjugate Market, By Linker Type, 2024-2032 (US$ Mn)
TABLE 65 North America Antibody Drug Conjugate Market, by Target, 2019-2023 (US$ Mn)
TABLE 66 North America Antibody Drug Conjugate Market, by Target, 2024-2032 (US$ Mn)
TABLE 67 North America Antibody Drug Conjugate Market, by Payload Type, 2019-2023 (US$ Mn)
TABLE 68 North America Antibody Drug Conjugate Market, by Payload Type, 2024-2032 (US$ Mn)
TABLE 69 North America Antibody Drug Conjugate Market, by Country, 2019-2023 (US$ Mn)
TABLE 70 North America Antibody Drug Conjugate Market, by Country, 2024-2032 (US$ Mn)
TABLE 71 United States Antibody Drug Conjugate Market, by Product, 2019-2023 (US$ Mn)
TABLE 72 United States Antibody Drug Conjugate Market, by Product, 2024-2032 (US$ Mn)
TABLE 73 United States Antibody Drug Conjugate Market, by Disease Type, 2019-2023 (US$ Mn)
TABLE 74 United States Antibody Drug Conjugate Market, by Disease Type, 2024-2032 (US$ Mn)
TABLE 75 United States Antibody Drug Conjugate Market, By Linker Type, 2019-2023 (US$ Mn)
TABLE 76 United States Antibody Drug Conjugate Market, By Linker Type, 2024-2032 (US$ Mn)
TABLE 77 United States Antibody Drug Conjugate Market, by Target, 2019-2023 (US$ Mn)
TABLE 78 United States Antibody Drug Conjugate Market, by Target, 2024-2032 (US$ Mn)
TABLE 79 United States Antibody Drug Conjugate Market, by Payload Type, 2019-2023 (US$ Mn)
TABLE 80 United States Antibody Drug Conjugate Market, by Payload Type, 2024-2032 (US$ Mn)
TABLE 81 Canada Antibody Drug Conjugate Market, by Product, 2019-2023 (US$ Mn)
TABLE 82 Canada Antibody Drug Conjugate Market, by Product, 2024-2032 (US$ Mn)
TABLE 83 Canada Antibody Drug Conjugate Market, by Disease Type, 2019-2023 (US$ Mn)
TABLE 84 Canada Antibody Drug Conjugate Market, by Disease Type, 2024-2032 (US$ Mn)
TABLE 85 Canada Antibody Drug Conjugate Market, By Linker Type, 2019-2023 (US$ Mn)
TABLE 86 Canada Antibody Drug Conjugate Market, By Linker Type, 2024-2032 (US$ Mn)
TABLE 87 Canada Antibody Drug Conjugate Market, by Target, 2019-2023 (US$ Mn)
TABLE 88 Canada Antibody Drug Conjugate Market, by Target, 2024-2032 (US$ Mn)
TABLE 89 Canada Antibody Drug Conjugate Market, by Payload Type, 2019-2023 (US$ Mn)
TABLE 90 Canada Antibody Drug Conjugate Market, by Payload Type, 2024-2032 (US$ Mn)
TABLE 91 Mexico Antibody Drug Conjugate Market, by Product, 2019-2023 (US$ Mn)
TABLE 92 Mexico Antibody Drug Conjugate Market, by Product, 2024-2032 (US$ Mn)
TABLE 93 Mexico Antibody Drug Conjugate Market, by Disease Type, 2019-2023 (US$ Mn)
TABLE 94 Mexico Antibody Drug Conjugate Market, by Disease Type, 2024-2032 (US$ Mn)
TABLE 95 Mexico Antibody Drug Conjugate Market, By Linker Type, 2019-2023 (US$ Mn)
TABLE 96 Mexico Antibody Drug Conjugate Market, By Linker Type, 2024-2032 (US$ Mn)
TABLE 97 Mexico Antibody Drug Conjugate Market, by Target, 2019-2023 (US$ Mn)
TABLE 98 Mexico Antibody Drug Conjugate Market, by Target, 2024-2032 (US$ Mn)
TABLE 99 Mexico Antibody Drug Conjugate Market, by Payload Type, 2019-2023 (US$ Mn)
TABLE 100 Mexico Antibody Drug Conjugate Market, by Payload Type, 2024-2032 (US$ Mn)
TABLE 101 Europe Antibody Drug Conjugate Market, by Product, 2019-2023 (US$ Mn)
TABLE 102 Europe Antibody Drug Conjugate Market, by Product, 2024-2032 (US$ Mn)
TABLE 103 Europe Antibody Drug Conjugate Market, by Disease Type, 2019-2023 (US$ Mn)
TABLE 104 Europe Antibody Drug Conjugate Market, by Disease Type, 2024-2032 (US$ Mn)
TABLE 105 Europe Antibody Drug Conjugate Market, By Linker Type, 2019-2023 (US$ Mn)
TABLE 106 Europe Antibody Drug Conjugate Market, By Linker Type, 2024-2032 (US$ Mn)
TABLE 107 Europe Antibody Drug Conjugate Market, by Target, 2019-2023 (US$ Mn)
TABLE 108 Europe Antibody Drug Conjugate Market, by Target, 2024-2032 (US$ Mn)
TABLE 109 Europe Antibody Drug Conjugate Market, by Payload Type, 2019-2023 (US$ Mn)
TABLE 110 Europe Antibody Drug Conjugate Market, by Payload Type, 2024-2032 (US$ Mn)
TABLE 111 Europe Antibody Drug Conjugate Market, by Country, 2019-2023 (US$ Mn)
TABLE 112 Europe Antibody Drug Conjugate Market, by Country, 2024-2032 (US$ Mn)
TABLE 113 Germany Antibody Drug Conjugate Market, by Product, 2019-2023 (US$ Mn)
TABLE 114 Germany Antibody Drug Conjugate Market, by Product, 2024-2032 (US$ Mn)
TABLE 115 Germany Antibody Drug Conjugate Market, by Disease Type, 2019-2023 (US$ Mn)
TABLE 116 Germany Antibody Drug Conjugate Market, by Disease Type, 2024-2032 (US$ Mn)
TABLE 117 Germany Antibody Drug Conjugate Market, By Linker Type, 2019-2023 (US$ Mn)
TABLE 118 Germany Antibody Drug Conjugate Market, By Linker Type, 2024-2032 (US$ Mn)
TABLE 119 Germany Antibody Drug Conjugate Market, by Target, 2019-2023 (US$ Mn)
TABLE 120 Germany Antibody Drug Conjugate Market, by Target, 2024-2032 (US$ Mn)
TABLE 121 Germany Antibody Drug Conjugate Market, by Payload Type, 2019-2023 (US$ Mn)
TABLE 122 Germany Antibody Drug Conjugate Market, by Payload Type, 2024-2032 (US$ Mn)
TABLE 123 France Antibody Drug Conjugate Market, by Product, 2019-2023 (US$ Mn)
TABLE 124 France Antibody Drug Conjugate Market, by Product, 2024-2032 (US$ Mn)
TABLE 125 France Antibody Drug Conjugate Market, by Disease Type, 2019-2023 (US$ Mn)
TABLE 126 France Antibody Drug Conjugate Market, by Disease Type, 2024-2032 (US$ Mn)
TABLE 127 France Antibody Drug Conjugate Market, By Linker Type, 2019-2023 (US$ Mn)
TABLE 128 France Antibody Drug Conjugate Market, By Linker Type, 2024-2032 (US$ Mn)
TABLE 129 France Antibody Drug Conjugate Market, by Target, 2019-2023 (US$ Mn)
TABLE 130 France Antibody Drug Conjugate Market, by Target, 2024-2032 (US$ Mn)
TABLE 131 France Antibody Drug Conjugate Market, by Payload Type, 2019-2023 (US$ Mn)
TABLE 132 France Antibody Drug Conjugate Market, by Payload Type, 2024-2032 (US$ Mn)
TABLE 133 United Kingdom Antibody Drug Conjugate Market, by Product, 2019-2023 (US$ Mn)
TABLE 134 United Kingdom Antibody Drug Conjugate Market, by Product, 2024-2032 (US$ Mn)
TABLE 135 United Kingdom Antibody Drug Conjugate Market, by Disease Type, 2019-2023 (US$ Mn)
TABLE 136 United Kingdom Antibody Drug Conjugate Market, by Disease Type, 2024-2032 (US$ Mn)
TABLE 137 United Kingdom Antibody Drug Conjugate Market, By Linker Type, 2019-2023 (US$ Mn)
TABLE 138 United Kingdom Antibody Drug Conjugate Market, By Linker Type, 2024-2032 (US$ Mn)
TABLE 139 United Kingdom Antibody Drug Conjugate Market, by Target, 2019-2023 (US$ Mn)
TABLE 140 United Kingdom Antibody Drug Conjugate Market, by Target, 2024-2032 (US$ Mn)
TABLE 141 United Kingdom Antibody Drug Conjugate Market, by Payload Type, 2019-2023 (US$ Mn)
TABLE 142 United Kingdom Antibody Drug Conjugate Market, by Payload Type, 2024-2032 (US$ Mn)
TABLE 143 Italy Antibody Drug Conjugate Market, by Product, 2019-2023 (US$ Mn)
TABLE 144 Italy Antibody Drug Conjugate Market, by Product, 2024-2032 (US$ Mn)
TABLE 145 Italy Antibody Drug Conjugate Market, by Disease Type, 2019-2023 (US$ Mn)
TABLE 146 Italy Antibody Drug Conjugate Market, by Disease Type, 2024-2032 (US$ Mn)
TABLE 147 Italy Antibody Drug Conjugate Market, By Linker Type, 2019-2023 (US$ Mn)
TABLE 148 Italy Antibody Drug Conjugate Market, By Linker Type, 2024-2032 (US$ Mn)
TABLE 149 Italy Antibody Drug Conjugate Market, by Target, 2019-2023 (US$ Mn)
TABLE 150 Italy Antibody Drug Conjugate Market, by Target, 2024-2032 (US$ Mn)
TABLE 151 Italy Antibody Drug Conjugate Market, by Payload Type, 2019-2023 (US$ Mn)
TABLE 152 Italy Antibody Drug Conjugate Market, by Payload Type, 2024-2032 (US$ Mn)
TABLE 153 Spain Antibody Drug Conjugate Market, by Product, 2019-2023 (US$ Mn)
TABLE 154 Spain Antibody Drug Conjugate Market, by Product, 2024-2032 (US$ Mn)
TABLE 155 Spain Antibody Drug Conjugate Market, by Disease Type, 2019-2023 (US$ Mn)
TABLE 156 Spain Antibody Drug Conjugate Market, by Disease Type, 2024-2032 (US$ Mn)
TABLE 157 Spain Antibody Drug Conjugate Market, By Linker Type, 2019-2023 (US$ Mn)
TABLE 158 Spain Antibody Drug Conjugate Market, By Linker Type, 2024-2032 (US$ Mn)
TABLE 159 Spain Antibody Drug Conjugate Market, by Target, 2019-2023 (US$ Mn)
TABLE 160 Spain Antibody Drug Conjugate Market, by Target, 2024-2032 (US$ Mn)
TABLE 161 Spain Antibody Drug Conjugate Market, by Payload Type, 2019-2023 (US$ Mn)
TABLE 162 Spain Antibody Drug Conjugate Market, by Payload Type, 2024-2032 (US$ Mn)
TABLE 163 Benelux Antibody Drug Conjugate Market, by Product, 2019-2023 (US$ Mn)
TABLE 164 Benelux Antibody Drug Conjugate Market, by Product, 2024-2032 (US$ Mn)
TABLE 165 Benelux Antibody Drug Conjugate Market, by Disease Type, 2019-2023 (US$ Mn)
TABLE 166 Benelux Antibody Drug Conjugate Market, by Disease Type, 2024-2032 (US$ Mn)
TABLE 167 Benelux Antibody Drug Conjugate Market, By Linker Type, 2019-2023 (US$ Mn)
TABLE 168 Benelux Antibody Drug Conjugate Market, By Linker Type, 2024-2032 (US$ Mn)
TABLE 169 Benelux Antibody Drug Conjugate Market, by Target, 2019-2023 (US$ Mn)
TABLE 170 Benelux Antibody Drug Conjugate Market, by Target, 2024-2032 (US$ Mn)
TABLE 171 Benelux Antibody Drug Conjugate Market, by Payload Type, 2019-2023 (US$ Mn)
TABLE 172 Benelux Antibody Drug Conjugate Market, by Payload Type, 2024-2032 (US$ Mn)
TABLE 173 Russia Antibody Drug Conjugate Market, by Product, 2019-2023 (US$ Mn)
TABLE 174 Russia Antibody Drug Conjugate Market, by Product, 2024-2032 (US$ Mn)
TABLE 175 Russia Antibody Drug Conjugate Market, by Disease Type, 2019-2023 (US$ Mn)
TABLE 176 Russia Antibody Drug Conjugate Market, by Disease Type, 2024-2032 (US$ Mn)
TABLE 177 Russia Antibody Drug Conjugate Market, By Linker Type, 2019-2023 (US$ Mn)
TABLE 178 Russia Antibody Drug Conjugate Market, By Linker Type, 2024-2032 (US$ Mn)
TABLE 179 Russia Antibody Drug Conjugate Market, by Target, 2019-2023 (US$ Mn)
TABLE 180 Russia Antibody Drug Conjugate Market, by Target, 2024-2032 (US$ Mn)
TABLE 181 Russia Antibody Drug Conjugate Market, by Payload Type, 2019-2023 (US$ Mn)
TABLE 182 Russia Antibody Drug Conjugate Market, by Payload Type, 2024-2032 (US$ Mn)
TABLE 183 Rest of Europe Antibody Drug Conjugate Market, by Product, 2019-2023 (US$ Mn)
TABLE 184 Rest of Europe Antibody Drug Conjugate Market, by Product, 2024-2032 (US$ Mn)
TABLE 185 Rest of Europe Antibody Drug Conjugate Market, by Disease Type, 2019-2023 (US$ Mn)
TABLE 186 Rest of Europe Antibody Drug Conjugate Market, by Disease Type, 2024-2032 (US$ Mn)
TABLE 187 Rest of Europe Antibody Drug Conjugate Market, By Linker Type, 2019-2023 (US$ Mn)
TABLE 188 Rest of Europe Antibody Drug Conjugate Market, By Linker Type, 2024-2032 (US$ Mn)
TABLE 189 Rest of Europe Antibody Drug Conjugate Market, by Target, 2019-2023 (US$ Mn)
TABLE 190 Rest of Europe Antibody Drug Conjugate Market, by Target, 2024-2032 (US$ Mn)
TABLE 191 Rest of Europe Antibody Drug Conjugate Market, by Payload Type, 2019-2023 (US$ Mn)
TABLE 192 Rest of Europe Antibody Drug Conjugate Market, by Payload Type, 2024-2032 (US$ Mn)
TABLE 193 Asia Pacific Antibody Drug Conjugate Market, by Product, 2019-2023 (US$ Mn)
TABLE 194 Asia Pacific Antibody Drug Conjugate Market, by Product, 2024-2032 (US$ Mn)
TABLE 195 Asia Pacific Antibody Drug Conjugate Market, by Disease Type, 2019-2023 (US$ Mn)
TABLE 196 Asia Pacific Antibody Drug Conjugate Market, by Disease Type, 2024-2032 (US$ Mn)
TABLE 197 Asia Pacific Antibody Drug Conjugate Market, By Linker Type, 2019-2023 (US$ Mn)
TABLE 198 Asia Pacific Antibody Drug Conjugate Market, By Linker Type, 2024-2032 (US$ Mn)
TABLE 199 Asia Pacific Antibody Drug Conjugate Market, by Target, 2019-2023 (US$ Mn)
TABLE 200 Asia Pacific Antibody Drug Conjugate Market, by Target, 2024-2032 (US$ Mn)
TABLE 201 Asia Pacific Antibody Drug Conjugate Market, by Payload Type, 2019-2023 (US$ Mn)
TABLE 202 Asia Pacific Antibody Drug Conjugate Market, by Payload Type, 2024-2032 (US$ Mn)
TABLE 203 China Antibody Drug Conjugate Market, by Product, 2019-2023 (US$ Mn)
TABLE 204 China Antibody Drug Conjugate Market, by Product, 2024-2032 (US$ Mn)
TABLE 205 China Antibody Drug Conjugate Market, by Disease Type, 2019-2023 (US$ Mn)
TABLE 206 China Antibody Drug Conjugate Market, by Disease Type, 2024-2032 (US$ Mn)
TABLE 207 China Antibody Drug Conjugate Market, By Linker Type, 2019-2023 (US$ Mn)
TABLE 208 China Antibody Drug Conjugate Market, By Linker Type, 2024-2032 (US$ Mn)
TABLE 209 China Antibody Drug Conjugate Market, by Target, 2019-2023 (US$ Mn)
TABLE 210 China Antibody Drug Conjugate Market, by Target, 2024-2032 (US$ Mn)
TABLE 211 China Antibody Drug Conjugate Market, by Payload Type, 2019-2023 (US$ Mn)
TABLE 212 China Antibody Drug Conjugate Market, by Payload Type, 2024-2032 (US$ Mn)
TABLE 213 Japan Antibody Drug Conjugate Market, by Product, 2019-2023 (US$ Mn)
TABLE 214 Japan Antibody Drug Conjugate Market, by Product, 2024-2032 (US$ Mn)
TABLE 215 Japan Antibody Drug Conjugate Market, by Disease Type, 2019-2023 (US$ Mn)
TABLE 216 Japan Antibody Drug Conjugate Market, by Disease Type, 2024-2032 (US$ Mn)
TABLE 217 Japan Antibody Drug Conjugate Market, By Linker Type, 2019-2023 (US$ Mn)
TABLE 218 Japan Antibody Drug Conjugate Market, By Linker Type, 2024-2032 (US$ Mn)
TABLE 219 Japan Antibody Drug Conjugate Market, by Target, 2019-2023 (US$ Mn)
TABLE 220 Japan Antibody Drug Conjugate Market, by Target, 2024-2032 (US$ Mn)
TABLE 221 Japan Antibody Drug Conjugate Market, by Payload Type, 2019-2023 (US$ Mn)
TABLE 222 Japan Antibody Drug Conjugate Market, by Payload Type, 2024-2032 (US$ Mn)
TABLE 223 India Antibody Drug Conjugate Market, by Product, 2019-2023 (US$ Mn)
TABLE 224 India Antibody Drug Conjugate Market, by Product, 2024-2032 (US$ Mn)
TABLE 225 India Antibody Drug Conjugate Market, by Disease Type, 2019-2023 (US$ Mn)
TABLE 226 India Antibody Drug Conjugate Market, by Disease Type, 2024-2032 (US$ Mn)
TABLE 227 India Antibody Drug Conjugate Market, By Linker Type, 2019-2023 (US$ Mn)
TABLE 228 India Antibody Drug Conjugate Market, By Linker Type, 2024-2032 (US$ Mn)
TABLE 229 India Antibody Drug Conjugate Market, by Target, 2019-2023 (US$ Mn)
TABLE 230 India Antibody Drug Conjugate Market, by Target, 2024-2032 (US$ Mn)
TABLE 231 India Antibody Drug Conjugate Market, by Payload Type, 2019-2023 (US$ Mn)
TABLE 232 India Antibody Drug Conjugate Market, by Payload Type, 2024-2032 (US$ Mn)
TABLE 233 South Korea Antibody Drug Conjugate Market, by Product, 2019-2023 (US$ Mn)
TABLE 234 South Korea Antibody Drug Conjugate Market, by Product, 2024-2032 (US$ Mn)
TABLE 235 South Korea Antibody Drug Conjugate Market, by Disease Type, 2019-2023 (US$ Mn)
TABLE 236 South Korea Antibody Drug Conjugate Market, by Disease Type, 2024-2032 (US$ Mn)
TABLE 237 South Korea Antibody Drug Conjugate Market, By Linker Type, 2019-2023 (US$ Mn)
TABLE 238 South Korea Antibody Drug Conjugate Market, By Linker Type, 2024-2032 (US$ Mn)
TABLE 239 South Korea Antibody Drug Conjugate Market, by Target, 2019-2023 (US$ Mn)
TABLE 240 South Korea Antibody Drug Conjugate Market, by Target, 2024-2032 (US$ Mn)
TABLE 241 South Korea Antibody Drug Conjugate Market, by Payload Type, 2019-2023 (US$ Mn)
TABLE 242 South Korea Antibody Drug Conjugate Market, by Payload Type, 2024-2032 (US$ Mn)
TABLE 243 South-East Asia Antibody Drug Conjugate Market, by Product, 2019-2023 (US$ Mn)
TABLE 244 South-East Asia Antibody Drug Conjugate Market, by Product, 2024-2032 (US$ Mn)
TABLE 245 South-East Asia Antibody Drug Conjugate Market, by Disease Type, 2019-2023 (US$ Mn)
TABLE 246 South-East Asia Antibody Drug Conjugate Market, by Disease Type, 2024-2032 (US$ Mn)
TABLE 247 South-East Asia Antibody Drug Conjugate Market, By Linker Type, 2019-2023 (US$ Mn)
TABLE 248 South-East Asia Antibody Drug Conjugate Market, By Linker Type, 2024-2032 (US$ Mn)
TABLE 249 South-East Asia Antibody Drug Conjugate Market, by Target, 2019-2023 (US$ Mn)
TABLE 250 South-East Asia Antibody Drug Conjugate Market, by Target, 2024-2032 (US$ Mn)
TABLE 251 South-East Asia Antibody Drug Conjugate Market, by Payload Type, 2019-2023 (US$ Mn)
TABLE 252 South-East Asia Antibody Drug Conjugate Market, by Payload Type, 2024-2032 (US$ Mn)
TABLE 253 Rest of Asia Pacific Antibody Drug Conjugate Market, by Product, 2019-2023 (US$ Mn)
TABLE 254 Rest of Asia Pacific Antibody Drug Conjugate Market, by Product, 2024-2032 (US$ Mn)
TABLE 255 Rest of Asia Pacific Antibody Drug Conjugate Market, by Disease Type, 2019-2023 (US$ Mn)
TABLE 256 Rest of Asia Pacific Antibody Drug Conjugate Market, by Disease Type, 2024-2032 (US$ Mn)
TABLE 257 Rest of Asia Pacific Antibody Drug Conjugate Market, By Linker Type, 2019-2023 (US$ Mn)
TABLE 258 Rest of Asia Pacific Antibody Drug Conjugate Market, By Linker Type, 2024-2032 (US$ Mn)
TABLE 259 Rest of Asia Pacific Antibody Drug Conjugate Market, by Target, 2019-2023 (US$ Mn)
TABLE 260 Rest of Asia Pacific Antibody Drug Conjugate Market, by Target, 2024-2032 (US$ Mn)
TABLE 261 Rest of Asia Pacific Antibody Drug Conjugate Market, by Payload Type, 2019-2023 (US$ Mn)
TABLE 262 Rest of Asia Pacific Antibody Drug Conjugate Market, by Payload Type, 2024-2032 (US$ Mn)
TABLE 263 Latin America Antibody Drug Conjugate Market, by Product, 2019-2023 (US$ Mn)
TABLE 264 Latin America Antibody Drug Conjugate Market, by Product, 2024-2032 (US$ Mn)
TABLE 265 Latin America Antibody Drug Conjugate Market, by Disease Type, 2019-2023 (US$ Mn)
TABLE 266 Latin America Antibody Drug Conjugate Market, by Disease Type, 2024-2032 (US$ Mn)
TABLE 267 Latin America Antibody Drug Conjugate Market, By Linker Type, 2019-2023 (US$ Mn)
TABLE 268 Latin America Antibody Drug Conjugate Market, By Linker Type, 2024-2032 (US$ Mn)
TABLE 269 Latin America Antibody Drug Conjugate Market, by Target, 2019-2023 (US$ Mn)
TABLE 270 Latin America Antibody Drug Conjugate Market, by Target, 2024-2032 (US$ Mn)
TABLE 271 Latin America Antibody Drug Conjugate Market, by Payload Type, 2019-2023 (US$ Mn)
TABLE 272 Latin America Antibody Drug Conjugate Market, by Payload Type, 2024-2032 (US$ Mn)
TABLE 273 Brazil Antibody Drug Conjugate Market, by Product, 2019-2023 (US$ Mn)
TABLE 274 Brazil Antibody Drug Conjugate Market, by Product, 2024-2032 (US$ Mn)
TABLE 275 Brazil Antibody Drug Conjugate Market, by Disease Type, 2019-2023 (US$ Mn)
TABLE 276 Brazil Antibody Drug Conjugate Market, by Disease Type, 2024-2032 (US$ Mn)
TABLE 277 Brazil Antibody Drug Conjugate Market, By Linker Type, 2019-2023 (US$ Mn)
TABLE 278 Brazil Antibody Drug Conjugate Market, By Linker Type, 2024-2032 (US$ Mn)
TABLE 279 Brazil Antibody Drug Conjugate Market, by Target, 2019-2023 (US$ Mn)
TABLE 280 Brazil Antibody Drug Conjugate Market, by Target, 2024-2032 (US$ Mn)
TABLE 281 Brazil Antibody Drug Conjugate Market, by Payload Type, 2019-2023 (US$ Mn)
TABLE 282 Brazil Antibody Drug Conjugate Market, by Payload Type, 2024-2032 (US$ Mn)
TABLE 283 Argentina Antibody Drug Conjugate Market, by Product, 2019-2023 (US$ Mn)
TABLE 284 Argentina Antibody Drug Conjugate Market, by Product, 2024-2032 (US$ Mn)
TABLE 285 Argentina Antibody Drug Conjugate Market, by Disease Type, 2019-2023 (US$ Mn)
TABLE 286 Argentina Antibody Drug Conjugate Market, by Disease Type, 2024-2032 (US$ Mn)
TABLE 287 Argentina Antibody Drug Conjugate Market, By Linker Type, 2019-2023 (US$ Mn)
TABLE 288 Argentina Antibody Drug Conjugate Market, By Linker Type, 2024-2032 (US$ Mn)
TABLE 289 Argentina Antibody Drug Conjugate Market, by Target, 2019-2023 (US$ Mn)
TABLE 290 Argentina Antibody Drug Conjugate Market, by Target, 2024-2032 (US$ Mn)
TABLE 291 Argentina Antibody Drug Conjugate Market, by Payload Type, 2019-2023 (US$ Mn)
TABLE 292 Argentina Antibody Drug Conjugate Market, by Payload Type, 2024-2032 (US$ Mn)
TABLE 293 Rest of Latin America Antibody Drug Conjugate Market, by Product, 2019-2023 (US$ Mn)
TABLE 294 Rest of Latin America Antibody Drug Conjugate Market, by Product, 2024-2032 (US$ Mn)
TABLE 295 Rest of Latin America Antibody Drug Conjugate Market, by Disease Type, 2019-2023 (US$ Mn)
TABLE 296 Rest of Latin America Antibody Drug Conjugate Market, by Disease Type, 2024-2032 (US$ Mn)
TABLE 297 Rest of Latin America Antibody Drug Conjugate Market, By Linker Type, 2019-2023 (US$ Mn)
TABLE 298 Rest of Latin America Antibody Drug Conjugate Market, By Linker Type, 2024-2032 (US$ Mn)
TABLE 299 Rest of Latin America Antibody Drug Conjugate Market, by Target, 2019-2023 (US$ Mn)
TABLE 300 Rest of Latin America Antibody Drug Conjugate Market, by Target, 2024-2032 (US$ Mn)
TABLE 301 Rest of Latin America Antibody Drug Conjugate Market, by Payload Type, 2019-2023 (US$ Mn)
TABLE 302 Rest of Latin America Antibody Drug Conjugate Market, by Payload Type, 2024-2032 (US$ Mn)
TABLE 303 Middle East Antibody Drug Conjugate Market, by Product, 2019-2023 (US$ Mn)
TABLE 304 Middle East Antibody Drug Conjugate Market, by Product, 2024-2032 (US$ Mn)
TABLE 305 Middle East Antibody Drug Conjugate Market, by Disease Type, 2019-2023 (US$ Mn)
TABLE 306 Middle East Antibody Drug Conjugate Market, by Disease Type, 2024-2032 (US$ Mn)
TABLE 307 Middle East Antibody Drug Conjugate Market, By Linker Type, 2019-2023 (US$ Mn)
TABLE 308 Middle East Antibody Drug Conjugate Market, By Linker Type, 2024-2032 (US$ Mn)
TABLE 309 Middle East Antibody Drug Conjugate Market, by Target, 2019-2023 (US$ Mn)
TABLE 310 Middle East Antibody Drug Conjugate Market, by Target, 2024-2032 (US$ Mn)
TABLE 311 Middle East Antibody Drug Conjugate Market, by Payload Type, 2019-2023 (US$ Mn)
TABLE 312 Middle East Antibody Drug Conjugate Market, by Payload Type, 2024-2032 (US$ Mn)
TABLE 313 UAE Antibody Drug Conjugate Market, by Product, 2019-2023 (US$ Mn)
TABLE 314 UAE Antibody Drug Conjugate Market, by Product, 2024-2032 (US$ Mn)
TABLE 315 UAE Antibody Drug Conjugate Market, by Disease Type, 2019-2023 (US$ Mn)
TABLE 316 UAE Antibody Drug Conjugate Market, by Disease Type, 2024-2032 (US$ Mn)
TABLE 317 UAE Antibody Drug Conjugate Market, By Linker Type, 2019-2023 (US$ Mn)
TABLE 318 UAE Antibody Drug Conjugate Market, By Linker Type, 2024-2032 (US$ Mn)
TABLE 319 UAE Antibody Drug Conjugate Market, by Target, 2019-2023 (US$ Mn)
TABLE 320 UAE Antibody Drug Conjugate Market, by Target, 2024-2032 (US$ Mn)
TABLE 321 UAE Antibody Drug Conjugate Market, by Payload Type, 2019-2023 (US$ Mn)
TABLE 322 UAE Antibody Drug Conjugate Market, by Payload Type, 2024-2032 (US$ Mn)
TABLE 323 Saudi Arabia Antibody Drug Conjugate Market, by Product, 2019-2023 (US$ Mn)
TABLE 324 Saudi Arabia Antibody Drug Conjugate Market, by Product, 2024-2032 (US$ Mn)
TABLE 325 Saudi Arabia Antibody Drug Conjugate Market, by Disease Type, 2019-2023 (US$ Mn)
TABLE 326 Saudi Arabia Antibody Drug Conjugate Market, by Disease Type, 2024-2032 (US$ Mn)
TABLE 327 Saudi Arabia Antibody Drug Conjugate Market, By Linker Type, 2019-2023 (US$ Mn)
TABLE 328 Saudi Arabia Antibody Drug Conjugate Market, By Linker Type, 2024-2032 (US$ Mn)
TABLE 329 Saudi Arabia Antibody Drug Conjugate Market, by Target, 2019-2023 (US$ Mn)
TABLE 330 Saudi Arabia Antibody Drug Conjugate Market, by Target, 2024-2032 (US$ Mn)
TABLE 331 Saudi Arabia Antibody Drug Conjugate Market, by Payload Type, 2019-2023 (US$ Mn)
TABLE 332 Saudi Arabia Antibody Drug Conjugate Market, by Payload Type, 2024-2032 (US$ Mn)
TABLE 333 Rest of Middle East Antibody Drug Conjugate Market, by Product, 2019-2023 (US$ Mn)
TABLE 334 Rest of Middle East Antibody Drug Conjugate Market, by Product, 2024-2032 (US$ Mn)
TABLE 335 Rest of Middle East Antibody Drug Conjugate Market, by Disease Type, 2019-2023 (US$ Mn)
TABLE 336 Rest of Middle East Antibody Drug Conjugate Market, by Disease Type, 2024-2032 (US$ Mn)
TABLE 337 Rest of Middle East Antibody Drug Conjugate Market, By Linker Type, 2019-2023 (US$ Mn)
TABLE 338 Rest of Middle East Antibody Drug Conjugate Market, By Linker Type, 2024-2032 (US$ Mn)
TABLE 339 Rest of Middle East Antibody Drug Conjugate Market, by Target, 2019-2023 (US$ Mn)
TABLE 340 Rest of Middle East Antibody Drug Conjugate Market, by Target, 2024-2032 (US$ Mn)
TABLE 341 Rest of Middle East Antibody Drug Conjugate Market, by Payload Type, 2019-2023 (US$ Mn)
TABLE 342 Rest of Middle East Antibody Drug Conjugate Market, by Payload Type, 2024-2032 (US$ Mn)
TABLE 343 Africa Antibody Drug Conjugate Market, by Product, 2019-2023 (US$ Mn)
TABLE 344 Africa Antibody Drug Conjugate Market, by Product, 2024-2032 (US$ Mn)
TABLE 345 Africa Antibody Drug Conjugate Market, by Disease Type, 2019-2023 (US$ Mn)
TABLE 346 Africa Antibody Drug Conjugate Market, by Disease Type, 2024-2032 (US$ Mn)
TABLE 347 Africa Antibody Drug Conjugate Market, By Linker Type, 2019-2023 (US$ Mn)
TABLE 348 Africa Antibody Drug Conjugate Market, By Linker Type, 2024-2032 (US$ Mn)
TABLE 349 Africa Antibody Drug Conjugate Market, by Target, 2019-2023 (US$ Mn)
TABLE 350 Africa Antibody Drug Conjugate Market, by Target, 2024-2032 (US$ Mn)
TABLE 351 Africa Antibody Drug Conjugate Market, by Payload Type, 2019-2023 (US$ Mn)
TABLE 352 Africa Antibody Drug Conjugate Market, by Payload Type, 2024-2032 (US$ Mn)
TABLE 353 South Africa Antibody Drug Conjugate Market, by Product, 2019-2023 (US$ Mn)
TABLE 354 South Africa Antibody Drug Conjugate Market, by Product, 2024-2032 (US$ Mn)
TABLE 355 South Africa Antibody Drug Conjugate Market, by Disease Type, 2019-2023 (US$ Mn)
TABLE 356 South Africa Antibody Drug Conjugate Market, by Disease Type, 2024-2032 (US$ Mn)
TABLE 357 South Africa Antibody Drug Conjugate Market, By Linker Type, 2019-2023 (US$ Mn)
TABLE 358 South Africa Antibody Drug Conjugate Market, By Linker Type, 2024-2032 (US$ Mn)
TABLE 359 South Africa Antibody Drug Conjugate Market, by Target, 2019-2023 (US$ Mn)
TABLE 360 South Africa Antibody Drug Conjugate Market, by Target, 2024-2032 (US$ Mn)
TABLE 361 South Africa Antibody Drug Conjugate Market, by Payload Type, 2019-2023 (US$ Mn)
TABLE 362 South Africa Antibody Drug Conjugate Market, by Payload Type, 2024-2032 (US$ Mn)
TABLE 363 Egypt Antibody Drug Conjugate Market, by Product, 2019-2023 (US$ Mn)
TABLE 364 Egypt Antibody Drug Conjugate Market, by Product, 2024-2032 (US$ Mn)
TABLE 365 Egypt Antibody Drug Conjugate Market, by Disease Type, 2019-2023 (US$ Mn)
TABLE 366 Egypt Antibody Drug Conjugate Market, by Disease Type, 2024-2032 (US$ Mn)
TABLE 367 Egypt Antibody Drug Conjugate Market, By Linker Type, 2019-2023 (US$ Mn)
TABLE 368 Egypt Antibody Drug Conjugate Market, By Linker Type, 2024-2032 (US$ Mn)
TABLE 369 Egypt Antibody Drug Conjugate Market, by Target, 2019-2023 (US$ Mn)
TABLE 370 Egypt Antibody Drug Conjugate Market, by Target, 2024-2032 (US$ Mn)
TABLE 371 Egypt Antibody Drug Conjugate Market, by Payload Type, 2019-2023 (US$ Mn)
TABLE 372 Egypt Antibody Drug Conjugate Market, by Payload Type, 2024-2032 (US$ Mn)
TABLE 373 Rest of Africa Antibody Drug Conjugate Market, by Product, 2019-2023 (US$ Mn)
TABLE 374 Rest of Africa Antibody Drug Conjugate Market, by Product, 2024-2032 (US$ Mn)
TABLE 375 Rest of Africa Antibody Drug Conjugate Market, by Disease Type, 2019-2023 (US$ Mn)
TABLE 376 Rest of Africa Antibody Drug Conjugate Market, by Disease Type, 2024-2032 (US$ Mn)
TABLE 377 Rest of Africa Antibody Drug Conjugate Market, By Linker Type, 2019-2023 (US$ Mn)
TABLE 378 Rest of Africa Antibody Drug Conjugate Market, By Linker Type, 2024-2032 (US$ Mn)
TABLE 379 Rest of Africa Antibody Drug Conjugate Market, by Target, 2019-2023 (US$ Mn)
TABLE 380 Rest of Africa Antibody Drug Conjugate Market, by Target, 2024-2032 (US$ Mn)
TABLE 381 Rest of Africa Antibody Drug Conjugate Market, by Payload Type, 2019-2023 (US$ Mn)
TABLE 382 Rest of Africa Antibody Drug Conjugate Market, by Payload Type, 2024-2032 (US$ Mn)

Frequently Asked Questions

What is the current size of the global antibody drug conjugate Market?

The global antibody drug conjugate market was valued at USD 9984.20 million in 2023.

What is the expected growth rate of the Antibody Drug Conjugate Market between 2024 and 2032?

The Antibody Drug Conjugate Market is expected to grow at a CAGR of 11.50% between 2024 and 2032, reaching USD 26594.21 million in 2032.

Which segment is leading the market share in terms of Product?

The Kadcyla segment is the leading segment by Product, holding a significant share of the market’s value in 2023.

Which Target governs the demand for Antibody Drug Conjugate globally?

The HER2 governs the demand for Antibody Drug Conjugate globally, holding a massive share in 2023.

Which Linker Type is expected to post the highest CAGR during the forecast period?

The Non-cleavable linkers segment is expected to post the highest CAGR during the forecast period.

Which region is fueling the growth of the Antibody Drug Conjugate industry?

The North America region is fueling the growth of the Antibody Drug Conjugate industry, with over a third of the market in 2023.

Who are the major players in the global antibody drug conjugate Market?

Seagen, Inc., (previously Seattle Genetics, Inc.); Takeda Pharmaceutical Company Ltd.; AstraZeneca PLC, F. Hoffmann-La Roche Ltd.; Pfizer, Inc.; ImmunoGen, Inc.; Gilead Sciences, Inc. (acquired Immunomedics); Daiichi Sankyo Company Ltd. are the major players in the global antibody drug conjugate Market.

What are the major market drivers of the Antibody Drug Conjugate industry?

The rising prevalence of cancer is significantly driving the growth of the Antibody Drug Conjugate industry. Moreover, significant R&D investments, increased demand for targeted therapies, and supportive regulatory environments collectively contribute to the expanding adoption and development of ADCs, ensuring improved treatment options for patients with cancer and other diseases.

What are the major market restraints of the Antibody Drug Conjugate industry?

The high development costs of Antibody Drug Conjugates (ADCs) significantly restrain market growth. Developing these drugs requires substantial investment in research, clinical trials, and regulatory approvals, creating a financial barrier, especially for smaller companies. Additionally, the complexity in manufacturing processes increases production costs and presents scalability challenges, limiting their widespread adoption.

What are the major market opportunities of the Antibody Drug Conjugate industry?

Purchase Options

Single User

$3699

Multi User

$4699

Enterprise

$5699

Request Free Sample

Have a question?

Don’t settle for less – trust Mitul to help you find the best solution.

Call: +91 6232 49 3207

EMAIL MITUL

Report delivery within 24 to 48 hours

– Other Info –

–What people say?-

I am very impressed with the information in this report. The author clearly did their research when they came up with this product and it has already given me a lot of ideas.

Jana Schmidt
CEDAR CX Technologies

– Connect with us –